The QualityStocks Daily Wednesday, December 11th, 2019

Today's Top 3 Investment Newsletters

StockMarketWatch (CEI) +308.16%

QualityStocks (UURAF) +56.61%

SmallCapRelations (NTRR) +28.57%

The QualityStocks Daily Stock List

Artelo Biosciences, Inc. (ARTL)

NetworkNewsWire, Zacks, StockPulse, Momentous News, Stockhouse, Market Exclusive, Stockwatch, Trading View, Investing.com, Simply Wall St, and Proactive Investors reported previously on Artelo Biosciences, Inc. (ARTL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company that centers on the development of therapeutics that modulate the endocannabinoid system. The Company is quickly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions. These include cancer, pain, and inflammation. The Company formerly went by the name Reactive Medical, Inc. It changed its name to Artelo Biosciences, Inc. in April of 2017. Established in 2011, Artelo Biosciences is headquartered in La Jolla, California.

The Company’s belief is that a biopharmaceutical approach will lead to novel and high-impact therapeutics that harness the full potential of the endocannabinoid system (ECS). The endocannabinoid system (ECS) is a widespread neuromodulatory system. It plays a vital role in human central nervous system (CNS) development, synaptic plasticity, and the response to endogenous and environmental insults.

Artelo Biosciences’ business model is to develop manifold pharmacological approaches to ECS modulation. Candidate therapeutic compounds within its current portfolio are based on targeting cannabinoid receptors and endocannabinoid transport inhibition.

Artelo’s pipeline encompasses many mechanisms for endocannabinoid system modulation. Specific programs now in development include ART27.13 – a high-potency GPCR Agonist (anorexia, cancer). Programs in development also include ART12.11 - proprietary cocrystal (multiple indications), and ART26.12 – a FABP5 Inhibitor (cancer, pain).

In November, Artelo Biosciences announced that positive non-clinical data with its Fatty Acid Binding Protein 5 (FABP5) inhibitor program under development in collaboration with The Research Foundation of the State University of New York Stony Brook, were published in the October 2019 issue of The Prostate, a premier peer-reviewed journal. (Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth, Carbonetti et. al, The Prostate, 2019, 1-11).

Mr. Gregory D. Gorgas, Chief Executive Officer of Artelo Biosciences, said, “We are very encouraged by the results of the combination of FABP5 inhibitors with standard of care therapy for prostate cancer. This data builds on previously published single-agent results in prostate cancer and we are looking forward to advance ART26.12, our FABP5 inhibitor program, toward human studies as rapidly as possible.”

This week, Artelo Biosciences announced the appointment of experienced industry executive Mr. John W. Beck to its Board of Directors. Mr. Beck brings over 31 years of financial and strategic operational experience, including 15 years at publicly traded life science companies. He is succeeding Georgia Erbez on the Board and has been appointed as Chair of the Audit Committee.

Artelo Biosciences, Inc. (ARTL), closed Wednesday's trading session at $2.20, off by 10.2041%, on 242,209 volume with 780 trades. The average volume for the last 3 months is 37,001 and the stock's 52-week low/high is $1.55309998/$12.00.

chart

Cardiol Therapeutics, Inc. (CRTPF)

Growstox, Market Screener, Investing News, NIC Investors, InvestorX, Stock Target Advisor, Invest Tribune, Stock Gumshoe, OTC Markets, Cannabis FN, and Stockhouse reported beforehand on Cardiol Therapeutics, Inc. (CRTPF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Cardiol Therapeutics, Inc. specializes in the research and commercial development of novel drug therapies using proprietary drug-delivery systems. The OTCQX-listed Company is a leader in the research and commercial development of pharmaceutical CBD (cannabidiol) and targeted therapies for inflammatory diseases. Cardiol is leveraging its expertise in pharmaceutical CBD to develop ultra-pure CBD products for commercialization in the billion dollar market for medicinal cannabinoids in Canada. Cardiol Therapeutics is headquartered in Oakville, Ontario.

Cardiol’s nanotherapeutics are based on a patented family of biocompatible and biodegradable amphiphilic block co-polymers made from polyethylene glycol (PEG) and polycaprolactone (PCL). PEG and PCL have a long history of safe use in humans. The Company’s proprietary nanoparticles have improved inherent stability and biocompatibility. They can also be customized to optimize the encapsulation and release characteristics of a wide spectrum of pharmaceuticals.

Cardiol Therapeutics has a view to expanding into Latin America and Europe, and to using nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs for the treatment of heart failure. It is taking advantage of its expertise in pharmaceutical cannabinoids to develop proprietary formulations for commercial development in three key medical markets. These include commercializing a line of pharmaceutically-manufactured pure cannabidiol products in the developing market for medical cannabinoids, developing nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs for the treatment of heart failure; and pursuing an immunotherapeutics program beginning with an innovative cancer immunotherapeutic in combination with cannabinoids for Glioblastoma Multiforme, a Fast Track eligible orphan indication.

The design of Cardiol’s proprietary nanotherapeutics are to increase the compatibility of drugs with the aqueous blood circulation, improve pharmacokinetics, and facilitate drug accumulation in the failing heart. The Company is also commercializing a line of pharmaceutically-manufactured pure cannabidiol products to address the growing market for medical cannabinoids. In collaboration with Dalton Pharma Services, Cardiol is developing innovative manufacturing expertise in the production of pharmaceutical cannabinoids in support of its nanotherapeutics program in heart failure.

Cardiol Therapeutics’ lead product is CardiolRx™. The design of it is to be one of the safest and most consistent cannabidiol formulations on the market. CardiolRx is pharmaceutically produced, manufactured under cGMP, and is THC free (less than 10 ppm). The Company’s plan is to commercialize CardiolRx in the billion-dollar market for medicinal cannabinoids in Canada and is also pursuing distribution opportunities in Europe and Latin America.

Cardiol Therapeutics, Inc. (CRTPF), closed Wednesday's trading session at $2.97, off by 1.3289%, on 5,652 volume with 21 trades. The average volume for the last 3 months is 11,808 and the stock's 52-week low/high is $1.62/$10.00.

chart

HempAmericana, Inc. (HMPQ)

Beat Penny Stocks, Stock of the Week, Investing.com, Simply Wall St, MicroSmallCap, GlobeNewswire, Epic Stock Picks, The Wolf of Penny Stocks, TMXmoney, Stockwatch, InvestorsHub, and Stockhouse reported earlier on HempAmericana, Inc. (HMPQ), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

HempAmericana, Inc. researches, develops, and sells products made of industrial hemp in the United States. The Company is an emerging participant in the CBD (cannabidiol) products market. It owns and operates a high-capacity, state-of-the-art CBD extraction and processing facility in Augusta, Maine. HempAmericana is headquartered in New York, New York. The Company’s shares trade on the OTC Markets.

The Company’s extraction and processing facility has a supersized supercritical CO2 extraction system, centrifugal partition chromatography refinement technology, and a mechanized fully-automated CBD bottling system. In addition, HempAmericana researches, develops, and sells products made of industrial hemp. This includes a popular brand of hemp rolling papers marketed under the brand name, “Rolling Thunders”.

HempAmericana’s CBD oil business uses the brand designation, “Weed Got Oil”. The Company continues to pursue an active place in the CBD white label market segment, principally for those companies seeking premium full-spectrum distillate CBD oil.

HempAmericana has purchased a 100-liter solvent recovery system, the Ecochyll X7 High Speed Evaporator. This system represents a 400 percent increase in evaporative capacity for the Company’s production line technology.

Today, HempAmericana announced that it is ready to launch its online payment processing engine following positive results from the full-spectrum CBD product formula testing recently completed by EVIO Labs, a best-in-class product testing and accreditation lab located in Berkeley, California. These results all confirm that HempAmericana’s products meet the legal limit for sale in the USA and internationally, remove all remaining barriers, allowing HempAmericana to commence processing online payments for CBD purchases via its new ecommerce sales portal.

HempAmericana recently sent seven full-spectrum CBD product formulas for analysis to EVIO Labs. This includes samples ranging from 125mg to 2500mg in potency. All samples were tested and received positive results, and the Company is now in full compliance with US and international regulatory standards for online payment processing of CBD products.

HempAmericana, Inc. (HMPQ), closed Wednesday's trading session at $0.005, up 4.0583%, on 4,993,122 volume with 104 trades. The average volume for the last 3 months is 6,384,585 and the stock's 52-week low/high is $0.004399999/$0.027699999.

chart

Parallax Health Sciences, Inc. (PRLX)

Market Exclusive, Proactive Investors, Market Screener, Last10k, Wallmine, Simply Wall St, Wallet Investor, Stockwatch, TMXmoney, VentureLine, 4-Traders, PR Newswire, TradingView, GlobeNewswire, InvestorsHub, and Stockhouse reported earlier on Parallax Health Sciences, Inc. (PRLX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Parallax Health Sciences, Inc. is an outcome-driven connected healthcare company. It allows for cost-effective remote diagnosis, treatment and monitoring of patients through proprietary platforms of integrated products and services. The Company’s products and offerings capitalize on the digital transformation in healthcare for improved patient compliance, diagnosis and treatment, and support healthcare system cost savings and efficiencies. Parallax Health Sciences lists on the OTC Markets Group’s OTCQB. The Company is headquartered in Santa Monica, California.

Parallax concentrates on personalized patient healthcare via its wholly owned subsidiaries, Parallax Health Management, Parallax Behavioral Health, and Parallax Diagnostics. The Company’s interoperable novel applications provide patients point-of-care testing and monitoring with information communicated through internet-based mobile phone applications, which are agnostic as to operating system. They are constructed on highly sophisticated data analytics.

Information is retrieved real-time by physicians who are monitoring patients with chronic diseases or through biometric feedback for health-related behavior modification. Information is automated for integration into electronic health records.

Parallax Health Management provides remote monitoring solutions. These solutions are to support disease management and provide better care options for chronic conditions.

Parallax Behavioral Health (PBH) provides consulting and software solutions to businesses and individuals. This is to improve value, margin, and performance by way of enhanced outcomes and lower cost mastery. PBH has its patented Intrinsic Code. This includes predictive-progressive analytics and goal optimization software. PBH is strategically positioned to enable users from large healthcare corporations to individuals take control of their outcomes.

Regarding Parallax Diagnostics, Parallax's Target Antigen Detection System (TADS) Diagnostic Platform is a Controlled Flow-Through Rapid Immunoassay Technology. It offers a variety of improved modifications and features to the traditional Flow-Through Immunoassay Test. With its Platform uniformity, vacuum pump, absorption layer for sample overflow, and complete compatibility with the Company’s optic reader, the Target System Diagnostics Platform is an inventive collection of tests for qualitative and quantitative detection of patient conditions.

Recently, Parallax Health Sciences announced its wholly-owned subsidiary, Parallax Behavioral Health, entered into vertical market licenses and technology integration agreements within the financial technology, human resource, lifestyle and healthcare fields.

Mr. Paul Arena, Chief Executive Officer of Parallax Health Sciences, said, ”Our data driven outcomes technology has application within several identified fields of use and we are fulfilling our commitment to our intellectual property monetization strategy by generating high gross margin revenue through licensing and enabling leading organizations with our technology to maximize our shareholder value.”

Parallax Health Sciences, Inc. (PRLX), closed Wednesday's trading session at $0.05, up 4.1667%, on 235,724 volume with 13 trades. The average volume for the last 3 months is 122,714 and the stock's 52-week low/high is $0.041000001/$0.279900014.

chart

The Flowr Corporation (FLWPF)

CannabisNewsWire, StockAP, Street Insider, MicroSmallCap, New Cannabis Ventures, Growstox, Trading View, CannabisMarketCap, Wallet Investor, NIC Investors, Proactive Investors, Equities, GlobeNewswire, Profit Confidential, and Cannabis Daily reported previously on The Flowr Corporation (FLWPF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

The Flowr Corporation, via its subsidiaries, holds a cannabis production and sales license granted by Health Canada. The Company expects to provide premium-quality cannabis to the adult-use recreational market and the medicinal market. It builds and operates large-scale, GMP-designed cultivation facilities using its own growing systems. The Flowr Corporation is based in Toronto, Ontario. The Company also has a production facility in Kelowna, British Columbia.

Flowr cultivates in advanced, state-of-the-art facilities, with its cannabis tended to by its team of experts. Flowr’s adult use products include Delahaze, Pink Kush, and Sensi Star. The Company’s medicinal products include BC Ice Cream, BC Delahaze, BC Durga Mata 2 CBD, BC Intergalactic Princess CBD, BC Lemon Thai Kush, BC Pink Kush, BC Sensi Star, and BC OG Sour Diesel.

This past August, The Flowr Corporation announced the completion of the acquisition of the remaining 80.2 percent interest in Holigen Holdings Limited via a share purchase agreement, as earlier announced on June 24, 2019. The acquisition creates an international cannabis company with access to 7 million square feet of anticipated low cost EU-GMP compliant outdoor grown cannabis in southern Portugal, to supply the developing and quickly growing European and Australasian medicinal cannabis markets.

Vinay Tolia, The Flowr Corporation’s Chief Executive Officer, said in August, “We are excited to complete the acquisition of Holigen and thereby add operations in Portugal and Australia to our existing Canadian platform. The combination of our extensive cannabis cultivation know-how and Holigen’s extensive pharmaceutical experience has the potential to create tremendous value. With an expected annual capacity of 500,000 kilograms, the Aljustrel cultivation asset in Portugal should allow us to be a significant producer in the global medical cannabis and active pharmaceutical ingredient (API) markets, initially in Europe and Australia-Asia.”

Since the beginning of Q3 2019, The Flowr Corporation completed its first outdoor and poly-film shade-house harvest from Flowr Forest, yielding roughly 3,100 kilograms. Moreover, the construction of Kelowna 1, the Company’s flagship indoor facility, is substantially complete. The final evidence package for licensing has been submitted to Health Canada for approval that when approved will double the number of grow rooms in operation.

The Flowr Corporation (FLWPF), closed Wednesday's trading session at $1.581, off by 3.0061%, on 21,304 volume with 56 trades. The average volume for the last 3 months is 63,220 and the stock's 52-week low/high is $1.33500003/$6.30000019.

chart

Verra Mobility Corporation (VRRMW)

Whale Wisdom, Business Wire, TeleTrader, All Penny Stocks, Stock Trends, Penny Stock Hub, Stock Consultant, Symbol Surfing, Financial Tailor, and Trade Ideas reported previously on Verra Mobility Corporation (VRRMW), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Verra Mobility Corporation focuses on solutions that help the world move safely and easily. The Company accomplishes this by building safe cities, smart roadways and the connected systems that tie them together. It provides smart mobility technology solutions and services in the USA, Canada, and Europe. Verra Mobility is based in Mesa, Arizona.

The Company works to understand new customers, regions and businesses that will shape tomorrow’s smart mobility experiences. This is all in an effort to ensure more people globally reach their destination safely and easily. Verra Mobility seamlessly connects people across the smart mobility ecosystem to important data they need to improve and simplify administrative processes.

Verra Mobility offers big data and visionary solutions. This is to make roadways around the world more efficient. It offers Commercial Fleet Toll Management; Rental Fleet Toll Management; and Parking Solutions. Concerning Safe Cities, the Company helps make cities safer for everyone through integrating hardware, software, and data to inform and enforce moving violations and solve crime.

While the Company is leading to a new era of smart mobility, it continues to honor the heritage of its legacy brands. These are Highway Toll Administration (HTA), American Traffic Solutions (ATS), and Euro Parking Collection (EPC).

Highway Toll Administration (HTA) is a service provider to rental agencies and fleet operators throughout North America. It is a private company contracted by its clients to provide tolling and violation management solutions. HTA is not affiliated with any government agencies.

American Traffic Solutions (ATS) is a leading provider of smart transportation solutions. These provide its customers with the highest level of convenience, safety, and value. The Company serves the nation’s largest fleets and rental car companies. ATS processes close to 50 million toll transactions and greater than 1 million violations annually.

Euro Parking Collection (EPC) specializes in the identification, notification, and collection of unpaid traffic and public transport related fees, charges, and penalties issued to foreign registered vehicles (FRV) or persons throughout Europe. EPC presently works on behalf of more than 450 issuing organizations in 15 European countries.

Yesterday, Verra Mobility announced the signing of the agreement to launch electronic toll payment for Rent A Car customers in France. At present, France has the most toll roads in Europe with 90 toll roads – all of which require payment in cash, by credit card or with an electronic transponder in a dedicated lane. Rental car customers are required to wait in toll lanes, paying by cash or credit card.

Verra Mobility’s service will enable electronic toll payments and speed up the travel experience. The tolling program with Rent A Car will enable rental car customers to use the dedicated electronic Liber-T lanes providing a quicker and more convenient driving experience without the bother of waiting and stopping to pay tolls.

Verra Mobility Corporation (VRRMW), closed Wednesday's trading session at $4.15, up 1.2195%, on 83,200 volume with 69 trades. The stock's 52-week low/high is $1.53999996/$5.23000001.

chart

Vireo Health International, Inc. (VREOF)

Born2Invest, New Cannabis Ventures, Midas Letter, TradingView, Stock Target Advisor, NIC Investors, Investing.com, Insider Financial, InvestorsHub, Investorideas, Stockwatch, Stockhouse, PR Newswire, and Market Screener reported previously on Vireo Health International, Inc. (VREOF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Vireo Health International, Inc. is a leading science-focused, multi-state cannabis company. Its mission is to build the cannabis company of the future through bringing the best of medicine, engineering, and science to the cannabis industry. Currently, the Company is licensed in eleven states and territories. These include Arizona, Maryland, Massachusetts, Minnesota, Nevada, New Mexico, New York, Ohio, Pennsylvania, Puerto Rico and Rhode Island. Vireo Health International is based in Minneapolis, Minnesota. Vireo Health of New York is a subsidiary of Vireo Health International.

Vireo provides best-in-class cannabis products and customer experiences. The Company cultivates cannabis in environmentally-friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at company-owned and third-party dispensaries.

Vireo Health integrates best-in-class medical, scientific, and engineering practices into the cannabis industry. Its commitment is to creating safe, all-natural cannabis-based products and a compassionate patient experience. The Company cultivates cannabis in their environmentally friendly greenhouses and manufactures pharmaceutical-grade cannabis extracts in their state-of-the-art labs. These products then sell through Vireo-owned dispensaries to qualifying patients in Minnesota and New York. The Company presently distributes its products by way of third-party dispensaries in Pennsylvania, Maryland and Ohio.

Vireo Health International’s products contain highly-purified, double-distilled, precisely formulated medical marijuana extracts with strain specific terpenes to maximize the entourage effect. The Company’s extracts and oral solutions include Vireo Red (19.1), Vireo Yellow (6.1), Vireo Green (1.1), Vireo Blue (6.1), and Vireo Indigo (19.1). These numbers represent the THC to CBD ratio.

Recently, Vireo Health International announced the launch of its new and unique Green Goods™ retail dispensary brand. The first Green Goods branded retail location opened on October 30, 2019, in Scranton, Pennsylvania offering customers cannabis products from Vireo and other state-licensed manufacturers.

Vireo plans to open a second Green Goods location in Bethlehem, Pennsylvania and a third location in Stroudsburg, Pennsylvania, pending regulatory approval. Vireo intends on launching all new dispensaries and renovating existing ones under the Green Goods banner.

Vireo Health International, Inc. (VREOF), closed Wednesday's trading session at $1.09132, up 9.9013%, on 56,780 volume with 70 trades. The average volume for the last 3 months is 111,293 and the stock's 52-week low/high is $0.879050016/$5.06264019.

chart

Dajin Resources Corp. (DJIFF)

StreetWise Reports, Penny Stock Tweets, GoldTelegraph, The Prospector News, 24hgold, Metals News, Investing News, Junior Mining Network, BullMarketNews, 4-Traders, Mining Feeds, StockInvest, Simply Wall St, and OTC Markets reported earlier on Dajin Resources Corp. (DJIFF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Dajin Resources Corp., together with its subsidiaries, mainly engages in the acquisition, exploration, and development of mineral properties in Canada, the United States, and Argentina. An early stage Lithium brine exploration company, Dajin, via its interest in Dajin Resources S.A. (Dajin S.A.), holds concessions or concession applications in Jujuy Province, Argentina, which were acquired in areas known to contain brines with Lithium, Potassium and Boron values. Dajin Resources has its corporate headquarters in Vancouver, British Columbia.

The land holdings in Jujuy Province, Argentina exceed 93,000 hectares (230,000 acres). They are chiefly situated in the Salinas Grandes and Guayatayoc salt lake basins. Dajin S.A. is partnered with Pluspetrol Resources Corporation B.V. - as operator is required to spend $2,000,000 to earn a 51 percent interest in Dajin S.A. Lithium properties.

The Phase One exploration program of the 4,400 hectares (10,873 acres) in San Jose-Navidad minas has completed the program where 25 shallow brine samples were taken. The assays returned Lithium brine concentrations ranging from 281 mg/l to 1,353 mg/l averaging 591 mg/l.

In addition, Dajin holds a 100 percent interest in 403 placer claims encompassing 7,914 acres (3,202 hectares) in the Teels Marsh valley of Mineral County, Nevada. These claims are known to contain Lithium and Boron values. They are next to the birth place of US Borax Corp's first borax mine.

Furthermore, Dajin holds a 100 percent interest in 145 placer claims encompassing 2,921 acres (1,182 hectares) in the Alkali Spring valley (also called Alkali Lake valley) of Esmeralda County, Nevada, positioned 7 miles (11 kilometers) northeast of Albemarle's Silver Peak Lithium brine operation in Clayton Valley.

In November of 2018, Dajin Resources announced the signing of a Definitive Agreement with Cypress Development Corp. (TSX-V: CYP) (OTCQB: CYDVF) for the exploration and development of Dajin Resources’ Alkali Spring valley Lithium property in Esmeralda County, Nevada. This property is 12 kilometers (7.5 miles) northeast of Cypress Development’s Clayton Valley Lithium project in Nevada. With this Agreement, Cypress will have the exclusive right and option to acquire a 50 percent undivided interest in Dajin Resources’ unpatented placer mining claims and application for water rights in Alkali Spring valley, Esmeralda County.

Recently, Dajin Resources reported that Pluspetrol Resources Corporation B.V. acquired 100 percent of the issued and outstanding common shares of LSC Lithium Corporation (LSC) for a cash consideration of about CDN $111 million. Dajin was partnered with LSC who has, by way of its wholly-owned subsidiary Lithium S Holding Corporation, an earn-in agreement to spend CDN $2,000,000 to earn a 51 percent interest in Dajin Resources S.A. Pluspetrol has created the company Litica Resources S.A. for exploration and development of its concessions.

Dajin Resources Corp. (DJIFF), closed Wednesday's trading session at $0.0199, up 64.4628%, on 60,999 volume with 7 trades. The average volume for the last 3 months is 52,406 and the stock's 52-week low/high is $0.0107/$0.056000001.

chart

Rare Element Resources Ltd. (REEMF)

Investor Village, StreetWise Reports, BacktestMarket, Junior Mining Network, Zacks, Insider Financial, TipRanks, Investing.com, Real Investment Advice, Dividend Investor, Northern Miner, Marketbeat, and Stockhouse reported earlier on Rare Element Resources Ltd. (REEMF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Rare Element Resources Ltd. is a mineral resource company based in Littleton, Colorado. The Company is focusing on delivering strategic materials to technology industries by advancing plans to develop the Bear Lodge Critical Rare Earth Project in northeast Wyoming. It owns a 100 percent interest in a group of 499 unpatented mining claims and 640 acres owned in patent. The mine site is about 12 miles northwest of the town of Sundance, Wyoming. Rare Element Resources’ shares trade on the OTCQB.

Additionally, Rare Element Resources has an option on a parcel of land positioned on the outskirts of the town of Upton, Wyoming, around 40 miles to the southwest. This is the planned site for the Project's hydrometallurgical processing plant.

Extensive geological work by Rare Element Resources since 2004, including drilling, geophysical and geochemical sampling and assaying, has resulted in a Measured & Indicated resource of 18 million tons grading 3.05% Total Rare Earth Oxide (TREO) at a 1.5% cut-off grade for the Bear Lodge Project. This includes 3.0 million tons of Measured and 15 million tons of Indicated resource.

The Bear Lodge Project is located in one of the best mining districts in the world. The Project is rich in “critical rare earths” (CREE), those elements that are less common, higher valued and expected to experience better demand growth and price support over the long term.

Regarding Rare Earths at the Bear Lodge Project, the deposits there contain 10 rare earth elements. Of these, five are identified as "critical" in the Department of Energy, Critical Materials Strategy Report published in 2011. These five element plus praseodymiun, that the Company includes due to its ability to be substituted for Neodymiun in high intensity permanent magnets, are expected to account for greater than 80 percent of the Project's projected revenues.

In February 2019, Rare Element Resources announced major progress on the third-party test work relating to its proprietary rare earth separation technology being conducted by Umwelt-und Ingenieurtechnik GmbH Dresden (UIT). UIT is an affiliate of Synchron, a significant shareholder of the Company. Rare Element Resources engaged UIT in April of 2018 to validate and further enhance its proprietary rare earth element processing technology.

UIT has advanced mineral and materials research capabilities in Dresden, Germany. UIT reported that its test work successfully validated Rare Element Resources’ proprietary technology and process flowsheet and identified additional opportunities for improvement.

Rare Element Resources Ltd. (REEMF), closed Wednesday's trading session at $0.615, up 28.125%, on 669,041 volume with 269 trades. The average volume for the last 3 months is 138,221 and the stock's 52-week low/high is $0.030099999/$0.709999978.

chart

Ucore Rare Metals, Inc. (UURAF)

Streetwise Reports, Micro Small Cap, Street Register, Trading View, Marketbeat, Wallet Investor, Northern Miner, and Stockhouse reported earlier on Ucore Rare Metals, Inc. (UURAF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Ucore Rare Metals, Inc. engages in the exploration and separation of rare earth elements in Canada and the U.S. Ucore is a development-phase company centered on rare metals resources, extraction and beneficiation technologies with near term potential for production, growth and scalability. The Company has a 100 percent ownership stake in Bokan-Dotson Ridge (Bokan). Bokan is the highest grade heavy rare earth project within the U.S. based on NI 43-101 standards. Ucore Rare Metals is based in Nova Scotia, Canada.

The Company’s vision and plan is to transition to become a foremost nanotechnology company that provides mineral separation products and services to the mining and mineral extraction industry. Its vision includes the development of a Strategic Metals Complex in Ketchikan, Alaska and the development of its rare earth minerals property at Bokan Mountain in Alaska.

Ucore Rare Metals announced, on March 31, 2014, the unanimous support of the Alaska State Legislature for Senate Bill 99 (2014) that authorized the AIDEA to issue up to USD $145 Million in bonds for the infrastructure and construction costs of the Bokan-Dotson Ridge Rare Earth Project. The Bokan Project is the Company’s main emphasis. The Project is 60 km southwest of Ketchikan, Alaska and 140 km northwest of Prince Rupert, British Columbia. It has direct ocean access to the western seaboard and the Pacific Rim.

Regarding Ucore’s SuperLig®-One pilot plant project, it has been engineered to accept a Pregnant Leach Solution (PLS). The initial output products are carbonate salts of the critical rare earth elements dysprosium, europium and terbium derived from the Bokan Dotson-Ridge Heavy REE Project in Southeast Alaska.

Regarding the Ray Mountains, Alaska Project, Ucore Rare Metals, through a wholly-owned operating subsidiary, holds claims on land selected for its mineral resource potential by the State of Alaska as part of the State’s land entitlement under the 1958 Alaska Statehood Act. The Company is planning expanded exploration once title transfer is tentatively approved by the federal government.

Ucore Rare Metals, Inc. (UURAF), closed Wednesday's trading session at $0.148, up 56.6138%, on 3,736,404 volume with 493 trades. The average volume for the last 3 months is 311,342 and the stock's 52-week low/high is $0.064999997/$0.25.

chart

PharmaCyte Biotech, Inc. (PMCB)

SmallCapNetwork, MyBestStockAlerts, Wall Street Corner, Penny Stock General, PennyStockInformer, Cannabis Financial Network News, BUYINS.NET, Fast Money Alerts, Penny Stock Beats, The Stock Psycho, Stock Shock and Awe, OTC Journal, Penny Stock Laboratory, Stock Market Media Group, InvestorPlace, Goldman Small Cap Research, Damn Good Penny Picks, Penny Picks, and Darth Trader reported earlier on PharmaCyte Biotech, Inc. (PMCB), and today choose to report on the Company, here at the QualityStocks Daily Newsletter.

PharmaCyte Biotech, Inc. concentrates on developing targeted treatments for cancer and diabetes applying its signature live cell encapsulation technology, Cell-in-a-Box®. This unique and patented technology is being used as a platform upon which treatments for many kinds of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. A clinical stage biotechnology Company and OTCQB-listed, PharmaCyte Biotech has its corporate office in Silver Spring, Maryland.

The Company is also working towards improving the quality of life of patients with advanced pancreatic cancer and on developing treatments for other kinds of solid cancerous tumors.  PharmaCyte’s treatment for pancreatic cancer involves low doses of the recognized anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form.

The capsules are placed as close to the cancerous tumor as possible. This is to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. The live-cell encapsulation technology that the Company employs is a way to enclose living cells in protective “cocoons” around the size of the head of a pin. It encapsulates living cells, not drugs. PharmaCyte Biotech is advancing its new treatment for pancreatic cancer into the clinic in the United States, with study sites in Australia and Europe.

Furthermore, the Company is developing treatments for cancer built upon chemical constituents of the cannabis  plant, called cannabinoids. PharmaCyte is studying ways to exploit the benefits of Cell-in-a-Box® technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects typically associated with cancer treatments.

Recently, PharmaCyte Biotech announced that its partner, Austrianova, successfully encapsulated the live cells used in PharmaCyte’s therapy for its planned clinical trial in patients with locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC). The cells are currently growing and dividing inside the Cell-in-a-Box® capsules.

PharmaCyte Biotech’s Chief Executive Officer, Mr. Kenneth L. Waggoner, said, “We are now in the process of monitoring the growth and division of the live cells as they spend more time in a ‘nutrient bath.’ This will allow the cells to continue to grow and divide and then completely fill the capsules. Once the capsules are completely full of live cells, they will be placed into syringes and frozen. Austrianova will then commence testing the capsules in the frozen syringes to finalize PharmaCyte’s clinical trial material.”

PharmaCyte Biotech, Inc. (PMCB), closed Wednesday's trading session at $0.0448, up 40.00%, on 12,844,204 volume with 703 trades. The average volume for the last 3 months is 2,125,351 and the stock's 52-week low/high is $0.031764999/$0.0678.

chart

Sports Field Holdings, Inc. (SFHI)

Penny Stock Hub, SmallCapVoice, Metals News, Market Screener, Streetwise Reports, OTC Markets, Dividend Investor, Emerging Growth, Stockhouse, InvestorsHub, Barchart, MarketWatch, and Stock of the Week reported previously on Sports Field Holdings, Inc. (SFHI), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Sports Field Holdings, Inc. engages in the design, engineering, and construction of eco-safe athletic facilities. The Company, by way of its wholly-owned subsidiary, FIRSTFORM, Inc., is a product development, engineering and design-build construction business. Sports Field considers itself a leader in innovative playing surfaces that focus on player safety and high performance athletic fields. OTCQB-listed, Sports Field Holdings has its head office in St. Charles, Illinois.

Sports Field engages in the design, engineering, construction, and construction management of athletic fields and sports complexes. In addition, the Company supplies its proprietary, technologically advanced, synthetic turf products and systems to the industry. Its two principal lines of business are construction management of sports facilities and synthetic turf sales. Sports Field says that these two lines of business can be categorized as design, development, and manufacturing of sports surfacing products and associated pre-engineered construction systems.

The Company’s FIRSTFORM® subsidiary supplies its proprietary patent-pending products, athletic field systems, and knowledge-based services to the athletic construction industry. For customers, a FIRSTFORM® Architect will customize their design plan. Additionally, a FIRSTFORM® Design Engineer will create their drainage plan. A FIRSTFORM® Project Manager will also manage the entire construction process.

Sports Field Holdings has its "PrimePlay" crumb rubber-free line of synthetic turf products. The Company’s flagship PrimePlay™ products are available and undergoing installation in athletic facilities across the U.S. Sports Field’s PrimePlay® Replicated Grass is crafted to closely mirror natural grass. It has a blade density almost three times greater than conventional artificial turf.

Sports Field also has its Primetrack Accel™ product line. This product features polyurethane derived from premium raw materials and secure traction and optimal slip protection. Primetrack Accel™ also features optimal force absorption, spike resistance, and is available in full range of color options. Primetrack Accel™ also features a uniform, consistent surface with durable performance.

Sports Field Holdings, Inc. (SFHI), closed Wednesday's trading session at $0.12, up 50%, on 7,000 volume with 2 trades. The average volume for the last 3 months is 1,722 and the stock's 52-week low/high is $0.07/$0.649999976.

chart

Manhattan Scientifics, Inc. (MHTX)

SmallCapVoice,  Xtremepicks,  The Penny Play,   FeedBlitz, Hawk Associates, StockHotTips, BullRally, OurHotStockPicks, AllPennyStocks, and HotStockChat reported earlier on Manhattan Scientifics, Inc. (MHTX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.  

Manhattan Scientifics, Inc.  concentrates on the commercialization of disruptive technologies in the nano-medicine space.  The OTCQB-listed Company is currently developing commercial medical prosthetics applications for its ultra-fine grain metals. Its goal is to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, (now Imagion Biosystems), its wholly-owned subsidiary. Manhattan Scientifics is based in New York, New York. The Company has an office in Albuquerque, New Mexico, and Montreal, Quebec.

Manhattan Scientifics has expertise in licensing from the national laboratories (the Los Alamos National Laboratory (LANL) and the Sandia National Laboratory (SNL)). Sandia National Laboratories is a multi-mission laboratory operated by National Technology and Engineering Solutions of Sandia LLC, a wholly-owned subsidiary of Honeywell International Inc., for the U.S. Department of Energy’s National Nuclear Security Administration.

Manhattan Scientifics has an agreement to collaborate with The University of Texas M.D. Anderson Cancer Center (MDACC) to advance, demonstrate, and validate an innovative technology developed by Mr. Edward R. Flynn, PhD, for the very early detection of cancer. The Company has delivered its pioneering cancer measurement instrument to MDACC.

Manhattan Scientifics focuses on technology transfer and commercialization of transformative technologies in the nano medicine space. The Company creates Intellectual Property (IP) portfolios and business cases supporting new technologies. It guides them to relationships with industrial partners who are well-prepared to launch product.  

The Company’s technology uses iron oxide nanoparticles and a technique it calls Magnetic Relaxometry to locate and measure cancers with a sensitivity that would provide a diagnosis years before other known methods. 

Currently, Manhattan Scientifics is centering on nanoparticle-based cancer detection via Senior Scientific. Moreover, it is focusing on nanostructured metals technology via wholly-owned subsidiary Metallicum, Inc.

Senior Scientific has  formed a research collaboration with Weill Cornell Medicine. For this alliance,  it will bring its magnetic relaxometry technology to Weill Cornell Medicine. Scientists will investigate the use of molecularly targeted nanoparticles to non-invasively detect and diagnose prostate cancers.

Manhattan Scientifics is also working on the start of product trials on its cancer detection product. The nanostructured metals technology has been revenue producing for some years. The cancer detection technology can detect cancer years earlier.

Manhattan Scientifics started as a technology incubator. Early in its history, the Company worked on acquiring a number of technologies in the fields of holographic data storage, water purification, alternative energy, advanced computer haptics and currently, nanotechnology. The Company’s chief source of latent commercial technologies are the U.S. government laboratories in New Mexico.

Manhattan Scientifics, Inc. (MHTX), closed Wednesday's trading session at $0.0157, up 37.7193%, on 238,984 volume with 20 trades. The average volume for the last 3 months is 191,441 and the stock's 52-week low/high is $0.003/$0.037999998.

chart

True Nature Holding, Inc.  (TNTY)

Real Pennies, MarketWatch, InvestorsHub, Marketwired, Stockhouse, and OTC Markets reported  on True Nature Holding, Inc.  (TNTY), and  today we are reporting on  the Company,  here at the QualityStocks Daily Newsletter. 

True Nature Holding, Inc.’s business plan considers a roll-up of businesses in the compounding pharmacy industry. The plan contemplates  manifold  acquisitions of businesses that  have conventionally operated locally, but that have specialty formulations  that  may have a larger market.  The Company is  targeting the acquisition of pharmacies that serve the human, and in some  cases, pet markets. True Nature Holding  has its corporate office in Atlanta, Georgia.

True Nature Holding’s focus is on the consolidation of the compound pharmacy industry.  Its plan is to acquire a series of businesses that specialize in compounding pharmacy activities,  primarily direct to consumers, and to doctors and veterinary professionals.  Pharmaceutical compounding is performed  in compounding pharmacies. It is the creation of a specific pharmaceutical product to fit the exclusive need of a patient.  

The Company  has acquired 100 percent of the membership interests of Newco4pharmacy, LLC. Newco4pharmacy is a development stage business targeted  at establishing a network of compounding pharmacies. 

True Nature  is creating a  blend  of human  and veterinary  businesses,  and  a balance of cash oriented operations, and more  usual  insurance based operations.  The Company expects to create three operating subsidiaries to hold its planned acquisitions, while maintaining its present holding company structure for the publicly held entity.  The expectation is that  all the new subsidiaries will be wholly-owned, single member LLC's, controlled and managed by the public company. 

True Nature Holding’s  intention is to  establish  a joint venture (JV) for-profit subsidiary; True Nature Community Health, Inc.  This will be owned by the public company, and  a newly formed not-for-profit entity; The True Nature Community Health Foundation. It is launching this new initiative targeted  at supporting the need for lower cost pharmaceuticals within the medically underserved small town and rural marketplaces.

True Nature Holding is in the process of acquiring  the  newly formed subsidiary; True Nature Community Health, Inc. (Community Health Subsidiary). It will have an 80 percent  ownership in the Community Health Subsidiary. The remaining 20 percent  ownership will be held by not-for-profit organizations.

Recently, True Nature Holding released an update to its shareholders on its strategy. This includes potential acquisitions, financing prospects, and its position concerning plans to participate in the Cryptocurrency and Blockchain space.

Regarding acquisitions, Dr. Jordan Balencic, Chairman, and interim Chief Executive Officer, said, "First, in alignment with our current business model, we have three near-term acquisition prospects at this time. The smallest is an asset acquisition involving the operating assets of a compounding pharmacy operation near West Palm Beach, Florida… Secondly, we have had some discussions with a group of investors who hold interests in a set of clinics, diagnostic facilities, and pharmacies, generally in Florida, mostly in the Dade and Broward county markets.”

Dr. Balencic continued, "We have continued conversations with other pharmacy operators with whom we have had long-term relationships, and subject to terms and financing, could move on those in early 2018 as well as the others previously mentioned."

True Nature Holding, Inc.  (TNTY), closed Wednesday's trading session at $0.0489, up 31.1168%, on 1,947,706 volume with 129 trades. The average volume for the last 3 months is 1,385,462 and the stock's 52-week low/high is $0.016/$0.219899997.

chart

The QualityStocks Company Corner

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

 Plus Products (CSE: PLUS) (OTCQX: PLPRF), a cannabis branded products company in the U.S., today announced the transition of its primary California distribution partner from Calyx Brands Inc. to HERBL Distribution Solutions for the company’s best-selling cannabis products. To view the full press release, visit http://cnw.fm/fgSj0. Also today, the company was highlighted in a publication from Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks, via its potcast site, www.potcasts.ca. Listen to the podcast: http://ibn.fm/LVCP1. Additionally, the company was featured today in a publication from CBDWire, examining how after the 2018 Farm Bill legalized industrial hemp, allowing farmers in all 50 states and tribes to grow the crop under state and tribal programs, the cannabidiol (CBD) industry exploded.

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Wednesday's trading session at $1.2251, up 2.9496%, on 39,970 volume with 45 trades. The average volume for the last 3 months is 49,809 and the stock's 52-week low/high is $1.08749997/$6.00810003.

Recent News

chart

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF)

The QualityStocks Daily Newsletter would like to spotlight Siyata Mobile Inc. (SYATF).

Siyata Mobile (TSX.V: SIM) (OTCQX: SYATF), a developer and provider of cellular communications solutions for enterprise workers and first responders, today announced its partnership with Tango Tango, a FirstNet Certified(TM) Push-to-Talk application and communications service provider, to offer the Uniden(R) UV350 dedicated in-vehicle device to its first responder customers in the United States. To view the full press release, visit http://nnw.fm/EE0mg.

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF) is a leading global developer and provider of Push-to-Talk Over Cellular ("PTT/PoC") systems for enterprise customers. The company specializes in connected vehicle products for professional fleets and markets its products under the Uniden® Cellular brand.

Since its inception in 2012, Siyata has amassed a customer base that includes cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia and the Middle East.

Recognized by the Toronto Venture Stock Exchange in 2018 as a Venture Top 50 Company, Siyata aims to deliver the highest quality and most technologically advanced mobile communication devices for global corporate workforces, fleets, homes and buildings.

The company has long been an industry pioneer, delivering the world's first 3G connected vehicle device as well as the world's first 4G/LTE vehicle mounted smartphone for First Responders and commercial fleets and vehicles.

Siyata is headquartered in Montréal, Québec, Canada.

Product Portfolio

Siyata's suite of technology includes numerous PTT and legacy devices, as well as cellular boosters designed to improve cellular signals in corporate warehouses, government embassies, retirement home campuses, banks and manufacturing plants.

The company's flagship product, the Uniden UV350, is the world's first vehicle-mounted 4G/LTE smartphone with crystal clear quality, carrier grade PTT, voice, text, video and data applications built into a single device. Specifically designed for First Responder and commercial fleet vehicles, the UV350 runs on cellular LTE networks that provide nationwide and global coverage, replacing traditional single purpose two-way radios that require a monthly fee and limited network coverage.

The Uniden UV350 is currently available through Bell Mobility, Canada's largest LTE network and PTT community. Expanding its availability, Siyata is completing network approval with two North American Tier 1 operators to launch the UV350 in the U.S. in 2019.

Management Team

CEO and Chairman Marc Seelenfreund is the founder of Siyata. He is also the founder of Siyata's parent company, Accel Telecom, an Israel-based company that specializes in importing and distributing innovative cellular and IP devices to fixed line operators and mobile providers within Israel. Prior to establishing Accel, Seelenfreund was a vice president at Sunrise Corporation in New York where he focused on financing publicly traded technology companies. Seelenfreund has a law degree from Bar Ilan University, is a board member at Israel's leading private university, and has served as an officer in the Israel Defense Forces.

Glenn Kennedy, vice president of sales, has over 25 years of sales experience in the telecommunications industry. Prior to joining Siyata in 2016, Kennedy managed sales nationally for Motorola Canada, HTC Communications Canada, and Sonim Technologies. He holds a bachelor's degree in honors business administration from the Richard Ivey School of Business at the University of Western Ontario.

CFO Gerald Bernstein, a professional chartered accountant, has spent 20 years focusing on private equity financing and tax efficient corporate structuring in multi-jurisdictional arenas. He holds a bachelor's degree of commerce as well as a graduate diploma in public accountancy from McGill University. Bernstein has been a member of the Canadian Institute of Chartered Accountants since 1987.

Gidi Bracha, Vice President of Technology, has served in this position since 2011 and spearheaded the development of both the Truckfone, Voyager and UV350. Bracha served in various key positions at Cellcom, Israel's leading cellular provider, including head of car mobility products and director of type approvals. Bracha served as an engineer technician in the Anti-Aircraft division of the Air Force in the Israel Defense Forces and holds a bachelor's degree in engineering and business management from the University of Derby.

Siyata Mobile Inc. (SYATF), closed Wednesday's trading session at $0.2677, up 2.1756%, on 141,385 volume with 16 trades. The average volume for the last 3 months is 87,465 and the stock's 52-week low/high is $0.198500007/$0.446249991.

Recent News

chart

Nightfood Holdings, Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings, Inc. (NGTF).

Nightfood Holdings (OTCQB: NGTF), the innovative company addressing America’s $50 billion annual night snacking spend, today announced that it has established discussions with Food & Beverage directors at a few of the largest hotel chains and management companies in the US. This news follows the company’s recent announcement that it hired MSourceIdeas and Mr. Lionel Binnie to spearhead major distribution through the hotel pantry and college campus verticals. To view the full press release, visit http://nnw.fm/4GhWK.

Nightfood Holdings, Inc. (OTCQB: NGTF), a pioneering consumer goods brand development company headquartered in Tarrytown, New York, owns Nightfood, Inc., creator of delicious, award-winning and better-for-you ice cream formulated by sleep and nutrition experts, and its wholly owned subsidiary MJ Munchies, Inc., which seeks to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. Known as “The Nighttime Snack Company,” Nightfood Inc. is focused on improving the late-night snacking choices of consumers while solving America’s $50 billion-dollar nighttime snacking problem.

Nightfood Ice Cream

Nightfood’s higher-protein and sleep-friendly ice cream won the 2019 Product of the Year Award in a survey of over 40,000 consumers. The annual Product of the Year survey, the world’s largest consumer-voted award for product innovation, is conducted by Kantar, a global leader in consumer research. In beating out the other finalists, consumers indicated that Nightfood’s one-of-a-kind innovation and unique value proposition made it a clear-cut winner in the ice cream space and a brand they were highly motivated to try. Winners of the 32-year-old award have been shown to outperform category sales performance by over 38 percent.

Less than two months since manufacturing their first pint of ice cream, Nightfood has now secured distribution in more than 13 states, and has received extensive media coverage from outlets such as USA Today, Fox Business’ Mornings With Maria, Parents Magazine, The Food Network, MarketWatch, The Washington Post, Business Insider, Bustle, and more.

With the Product of the Year award and millions in media coverage, Management has publicly stated their goal of securing nationwide distribution in over 10,000 retail outlets by March 31, 2020.

Formulated by leading sleep and nutrition experts, including America’s most prominent sleep expert, Dr. Michael Breus, Nightfood’s higher protein/higher fiber, and lower sugar ice cream delivers great ice cream taste and texture, while minimizing sleep-disruptive ingredients such as caffeine, excess sugar, and excess fat and calories. The addition of certain minerals, enzymes and amino acids, which research suggests can support sleep quality, is another bonus. Nightfood only uses hormone-free milk, is certified Kosher, and offers eight original flavors, five of which are gluten-free. Nightfood ice cream also uses all-natural sweeteners with no Erythritol, no sucralose, or other artificial sweeteners.

More than 37,000 consumers across the country have already requested coupons for the company’s newly launched Nightfood ice cream by entering a giveaway hosted at NightfoodIceCream.com which includes a chance to win a one-year supply (96 pints) plus a freezer for storage. The coupon program is being run in conjunction with PromotionPod, which has previously conducted successful campaigns for brands such as Chobani, Halo Top, and BodyArmor.

Nightfood Inc. began its nationwide rollout of Nightfood ice cream in February 2019, successfully securing placement in Meijer supermarket locations in the Midwest with a concentration around the metropolitan areas of Chicago, Detroit, Indianapolis, Columbus and Milwaukee. A distribution agreement with New England Ice Cream Corporation (NEIC) will also place Nightfood ice cream in outlets located throughout Massachusetts, Vermont, New Hampshire, Maine, Rhode Island and Connecticut.

Ice cream lovers in northern California will find Nightfood Ice Cream at various upscale, independent retail outlets in and around the San Francisco bay area serviced through a distribution agreement with Wonder Ice Cream Company, which services thousands of retail outlets from Bakersfield north to the Oregon border. Consumers can also purchase Nightfood ice cream online at BuyNightfood.com through the Company’s partnership with IceCreamSource.com.

Ice cream is now the 2nd most popular night snack choice, with almost half of all consumers reaching for ice cream after dark. According to IRI Worldwide, 44 percent of all snack consumption occurs between dinner and bedtime, representing a consumer spend of over $1 billion weekly on nighttime snacks in the U.S. alone. Market research giant Mintel recently released a report identifying nighttime specific food and beverages as one of their most “compelling and category changing” trends for 2017 and beyond.

Nightfood has developed a dynamic infographic resource that clearly illustrates the size and scope of the largely untapped nighttime snack category (http://NightSnacking.com). Americans everywhere are likely to identify with the infographic’s results that vividly illustrate late night snacking by age group, popular snack choice, and amount of money spent each week on feeding after-hour snack attacks. Available in eight delicious flavors, Nightfood ice cream can help consumers satisfy nighttime cravings in a better, healthier, more sleep-friendly way.

MJ Munchies, Inc.

MJ Munchies, Inc., was formed in 2018 as a new, wholly owned subsidiary of Nightfood Holdings, Inc. to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. The Company intends to market some of these new products under the trademarked brand name “Half-Baked” and has entered into a Letter of Intent that allows Global Consortium Inc. (OTC: GCGX) subsidiary Infused Edibles to receive an exclusive license to manufacture and distribute marijuana and CBD-infused products under the Half-Baked brand.

Management believes the Half-Baked brand will give the Company a unique and defensible competitive advantage against other recreational edible brands. The Company believes tremendous opportunities currently exist to launch successful and legally compliant products in this space, and that such opportunities will continue to grow over time.

Management Team

Nightfood founder and CEO Sean Folkson is a formerly frustrated nighttime snacker whose late-night cravings led him to seek a better solution for himself and others through the creation, marketing and distribution of the Nightfood product line. Folkson also founded internet marketing company AffiliatePros.com which provided the startup capital to launch Specialty Equipment Direct, an online distributor of floor removal equipment that quickly grew to 7-figure revenues. Folkson received a bachelor’s degree in business administration with a concentration in marketing from S.U.N.Y Albany, New York, in 1991.

Jim Christensen, vice president of Nightfood Ice Cream, is the former Vice President of Ice Cream Sales with global ice cream giant Unilever. In his over 20 years at Unilever, Jim led sales and distribution initiatives for brands such as Ben & Jerry’s, Klondike, Breyers and Good Humor. Christensen joined the Nightfood team in June of 2018 with the directive to launch Nightfood ice cream rapidly into national distribution through supermarket, drug, convenience and other channels. Understanding that the overwhelming majority of at-home ice cream consumption occurs in the hours before bed, Christensen has identified Nightfood as the next evolution in better-for-you ice cream.

CFO Mark Noffke, CPA, has over 37 years of experience as a seasoned financial and management professional. He has served as chief financial officer of several small cap public companies since 2004 where he oversaw virtually every aspect of the company’s operations, administration, customer service and human resources. Noffke has a bachelor’s degree in accounting from Valparaiso University in Indiana.

Advisory Board

The Nightfood advisory board includes Tom Morse, founder of 5-Hour Energy and Living Essentials, LLC.; Doron Stern, former vice president of marketing at Chobani and Popcorn, Indiana; restaurateur and celebrity Chef Chris Santos; Paul Jarrett, CEO of fast-growing nutrition startup BuluBox; Eric Egeland, president of Capacity Consulting Inc.; Dr. Michael A. Grandner, director/Sleep and Health Research Program at the University of Arizona; Dr. Michael Breus, sleep expert and best-selling author known to millions as The Sleep Doctor(TM); Dr. Lauren Broch, resident nutrition, sleep disorder expert and a member of the scientific advisory board.

Nightfood Holdings, Inc. (NGTF), closed Wednesday's trading session at $0.26, up 8.3333%, on 138,486 volume with 36 trades. The average volume for the last 3 months is 147,496 and the stock's 52-week low/high is $0.165999993/$0.920000016.

Recent News

chart

HTC Extraction Systems (TSX.V: HTC)

The QualityStocks Daily Newsletter would like to spotlight HTC Extraction Systems (TSX.V: HTC).

HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF), a hemp biomass cultivation, extraction, formulation and refining entity, is positioned for a truly soaring bottom line driven by major investments and acquisitions in the fast-growing cannabidiol (CBD) and cannabinoid market. The company recently closed a private placement with gross proceeds of $10 million to finance 25 million units of the company (http://cnw.fm/8fBRa) – proceeds used to fund growth plans.

HTC Extraction Systems (TSX.V: HTC) has developed and optimized proprietary technologies designed for biomass extraction, distillation and purification of ethanol and ethanol-based solvents used for the hemp biomass and cannabidiol (“CBD”) industry, as well as gas and liquid extraction. HTC’s extraction & purification systems are engineered to large-scale to reduce capital and operating costs while delivering superior performance measured by reduced energy usage, lowered emissions and improved quality of the product produced.

Advanced Extraction Technologies

For more than 14 years, HTC has developed and optimized proprietary technology and purification systems used for biomass, gas and liquid extraction. These technologies include:

  • LCDesign® – Low-cost design for modular gas, liquid and biomass extraction systems optimizes plant design, thus reducing capital and operating costs.
  • PDOEngine™ – Software-based design algorithms accurately model and simulate gas, liquid and biomass extraction processing.
  • Delta Solvents™ – Custom-designed, ethanol-based solvent mixtures and additives that optimize production and reduce costs. Technology development is being conducted at HTC’s sponsored research facilities at the University of Calgary.

Delta Purification® Technology

HTC’s patented Delta Purification® technology will purify, recycle and reuse the extraction ethanol used in the CBD extraction process while managing and reducing any CBD waste losses through the re-extraction of all wastes collected from the purified ethanol. Current and new technologies include:

  • Delta CBD Reclaiming System: Reclaiming and purifying ethanol for use in CBD extraction from biomass. Reduces required heat to prevent damage of the chemical attributes of the CBD molecule, allowing extracted CBD to meet food-grade targets for human consumption.
  • Delta Solvent Reclaiming System: Reclaiming and purifying ethanol-based solvents, such as single, mixed and formulated amines, for use in natural gas processing and post-combustion CO2 capturing processes.
  • Delta Glycol Reclaiming System: Reclaiming and purifying glycols, such as mono-ethylene glycol and tri-ethylene glycol for use in natural gas dehydration processes.

Hemp Biomass and Tolling Contracts

HTC has entered into a hemp biomass tolling agreement for the 2019 crop year involving a supply of hemp biomass from a hemp grower in Saskatchewan, Canada. The hemp grower utilizes five varieties of Health Canada-approved cultivars as the genetic foundation. HTC will process and extract CBD FSO distillate from the hemp biomass. As a tolling fee payment, HTC will receive a percentage of the extracted CBD FSO distillate for its processing, extraction, purification and distillation services.

Additional hemp biomass tolling contracts with producers and hemp biomass providers are being negotiated in the U.S. for the 2020 hemp crop growing year. HTC will provide “local-to-grower” drying-to-biomass storage capability and transportation of dried biomass to an HTC, location to be determined, future US based, extraction facility. HTC is also in negotiation with a 60,000-acre, recognized Canadian farm leader, who is a significant hemp biomass producer, for a similar hemp biomass tolling contract.

re3™ Technology

Large users of ethanol and solvents for plant oil extraction demand reduced capital and operating costs. HTC’s re3™ (reclaim, recycle, reuse) technology can save up to 30% of the required fluid costs. The increasing cost of new extraction ethanol, combined with the cost of used ethanol disposal, creates a unique opportunity whereby the re3™ technology will create cost savings, while meeting environmental responsibilities.

The growth of ethanol and CO2 used in CBD production has created a new demand for reliable commercial scale ethanol reclaimer systems. The Delta Purification® ethanol system meets this new demand.

Sales and Offtake Agreements

HTC intends to leverage its relationship with its related entity, Purely Canada Foods™, to provide sales and distribution for its Ingredient CBD market under the brand of Purely Canada Hemp™, Purely Canada CBD™, Purely Canada Cannabinoids™. Purely Canada Hemp™ will develop risk managed multi-year ingredient supply contracts with its existing and new Global Food, Beverage and Animal Food Industry Customers.

Project Construction

HTC has focused the Canadian implementation of its BOOM (build, own, operate and maintain) extraction tolling strategy on a location near Regina, Saskatchewan. HTC is currently constructing a 19,000-square-foot GMP Euro compliant extraction tolling facility on six acres of land that will include biomass processing, extraction, implementation of DeltaSolv™ technologies and Delta Purification® systems, distillate and refining equipment, laboratory quality control and testing operations, and on-site office and admin facilities.

Leadership

Chairman, CEO and Director Lionel Kambeitz is a recognized professional in business development and international business relations. He has played a founding role in many other Canadian and U.S.-based companies. Kambeitz has executive experience in a variety of industries including energy, agriculture, food production engineering, and manufacturing.

Jeff Allison, Senior Vice President, Chief Financial Officer and Director, has over 20 years of experience in corporate finance and business development. Prior to joining HTC in 2005, Allison as Vice President assisted with the founding and setup of CUCORP Financial Services in Saskatchewan.

HTC Extraction Systems (TSX.V: HTC), closed Wednesday's trading session at $0.195, up 2.6316%, on 10,000 volume with 3 trades. The average volume for the last 3 months is 131,912 and the stock's 52-week low/high is $0.079999998/$1.24.

Recent News

chart

Sproutly Canada, Inc. (OTCQB: SRUTF) (CSE: SPR) (FRA: 38G)

The QualityStocks Daily Newsletter would like to spotlight Sproutly Canada, Inc. (SRUTF).

Sproutly Canada, Inc. (CSE:SPR) (OTCQB:SRUTF) (FSE:38G) is pleased to announce the delivery of its first shipment of CALIBER flower to Alberta Gaming, Liquor & Cannabis (“AGLC”), marking its entrance into Canada’s recreational cannabis market. Adult recreational cannabis consumers in Alberta will soon have the opportunity to enjoy CALIBER’s Berry White and Lemon Z strains which will be available for purchase on Alberta’s only legal online recreational cannabis store, AlbertaCannabis.org as well as in many of the over 350 licensed physical cannabis retailers, the most out of any Canadian province. This news immediately follows the announcement from December 3rd, 2019, that Sproutly’s wholly-owned subsidiary Toronto Herbal Remedies (“THR”) signed a Supply Agreement with AGLC.

Sproutly Canada, Inc. (OTCQB: SRUTF) (TSX.V: SPR) (FRA: 38G) is developing and bringing to market cannabis consumer products with a focus on beverages. The company’s core mission is to become the leading supplier of water-soluble cannabis solutions and bio-natural oils for brands in the emerging cannabis beverage and edibles market.

To make this happen, Sproutly acquired Infusion Biosciences to bring to market a patent-pending Aqueous Phytorecovery Process (APP) technology, a fundamental paradigm shift within the cannabis industry. Replacing traditional water-compatible solutions with true natural water solubility improves the body’s ability to utilize cannabinoids, making the effect of the cannabis almost immediate.

This revolutionary process doesn’t alter the cannabis compounds and provides an onset time and offset time that mimics the same effects as inhaled marijuana. That means consumers may feel effects in five minutes or less and be free from the desired effect in approximately 90 minutes—a vastly different ingestion pattern than current methods. In addition, the water-based cannabinoids can be mixed with other liquids and stay dissolved in those liquids. The application of water-soluble cannabis infusions has potential to be widespread in both medicinal and recreational cannabis sectors, giving Sproutly a distinctive edge in a market with untapped potential.

Sproutly’s business model is focused on processing rather than cultivating, which means its success is not constrained to growing its own cannabis. The company does own a Toronto-based, ACMPR-licensed facility designed and built with a focus on cultivating pharmaceutical-grade cannabis to produce and formulate the first natural, truly water-soluble cannabis solution. Its water-soluble ingredients and bio-natural oils will deliver revolutionary brands to international markets that are searching for well-defined commercial products.

Sproutly’s entrance in the cannabis market is perfectly timed as cannabis is moving towards mainstream acceptance. Potential users are, however, interested in consuming cannabis products as drinks and using it as oils rather than smoking. The potential cannabis beverage market is staggering, and with Sproutly owning the exclusive rights to APP technology in Canada, Australia, Jamaica, Israel and the entire European Union, the company is looking at significant international expansion opportunities.

Sproutly plans to capitalize on these international opportunities by executing on partnerships with local and globally established consumer brands to leverage their existing customer bases, expand brand loyalty, and assist with marketing and support distribution networks to deliver scientific breakthroughs with speed and efficiency?worldwide.

Management

Sproutly believes that talent drives growth. The company is committed to bringing together the best and brightest minds in the cannabis space to help with their mission to disrupt the global beverage and consumables market.

President, CEO and Director Keith Dolo recently served for more than 13 years with Robert Half, an S&P 500, NYSE-listed company. At Robert Half, Dolo held the position of vice president for more than eight years, as well as other senior roles in both operations and sales. He also sits on an advisory committee and a board position for two nonprofits in Vancouver, BC.

Chief Science Officer and Director Dr. Arup Sent has more than 35 years of experience in research and executive management at biotechnology and pharmaceutical companies. He was awarded a PhD in biochemistry from Princeton University and is a former faculty member at the National Cancer Institute and Scripps Research Institute. Sen is the inventor on five U.S. patents and numerous international patents and patent-pending applications.

Chief Financial Officer Craig Loverock is a chartered professional accountant with over 20 years of experience in accounting and finance roles in Canada, the United States and the United Kingdom. He has extensive expertise in public company reporting and transactional experience, having served as the senior financial advisor to the chairman at Magna International and acting as chief compliance officer and CFO for a private equity firm.

Head Grower Frank Han has over 12 years of experience in the horticulture industry. A previous master grower in a large commercial facility, Han has impressive expertise in all growing methods, techniques and procedures. He brings with him a wealth of knowledge in cloning, nutrient and overall plant management. Han will be in charge of the production team at Sproutly’s Toronto Herbal Remedies facility.

Sproutly Canada, Inc. (OTCQB: SRUTF), closed Wednesday's trading session at $0.1648, up 9.8667%, on 77,575 volume with 35 trades. The average volume for the last 3 months is 208,456 and the stock's 52-week low/high is $0.140475004/$0.850000023.

Recent News

chart

VPR Brands, LP (VPRB)

The QualityStocks Daily Newsletter would like to spotlight VPR Brands, LP (VPRB).

VPR Brands, LP (VPRB) was featured today in a publication from HempWireNews, examining how hemp is an extremely versatile crop. It is used to make paper, textiles, biodegradable plastics and fuel among a plethora of applications. Not to mention the extremely useful and popular hemp extract cannabidiol (CBD). However, one of hemp’s most exciting applications is in construction.

Florida-based VPR Brands, LP (VPRB) is an innovative technology holding company whose assets include patented atomization-related products and technology. VPR Brands' current lineup of products includes accessories and vaporizers for cannabidiol (CBD), cannabis concentrates and extracts. The company is also engaged in product development within the vaping market and partners with top international brands to elevate their products within the vaping industry.

VPR Brands employs a growth strategy centered on high-performance, high-quality products that build exponential brand equity, awareness and loyalty. The company's current product portfolio is comprised of the following:

  • GoldLine combines premium ingredients and extracts coupled with the newest in technology to achieve the ultimate selection of cannabidiol (CBD) and hemp-based products available anywhere. The product range is designed for a wide variety of consumers and features edibles such as gummies and pure honey stix, tinctures, pre-rolled flower, vapable products and creams. For more information please visit www.cbdgoldline.com.
  • HoneyStick is a lifestyle brand that combines the features of high tech, high performance, dependability and affordability when it comes to upper tier vaporizers. HoneyStick was first to market in creating a Sub Ohm vaporizer to the latest Ripper and Plasma GQ. The HoneyStick team works with a vast network of growers, extractors and industry figures to bring the needs of patients and recreational users to life. HoneyStick is sold online and through a diverse network of distributors, e-tailers, dispensaries and smoke shops. For more information about HoneyStick, visit www.vapehoneystick.com.
  • Helium brings the vaping experience to a new level with intense flavors that are steeped to perfection and chilled at 20 degrees below room temperature. Helium's chillers are scientifically proven to preserve flavor, freshness and aroma. Helium is in a 50ml durable and squeezable bottle with drip tip that is functional from the start, engineered to deliver 77 percent VG.
  • Vaporin delivers Sub Ohm series starter kits. Vaporin also provides an eye-catching display case with multi-packs of selected starter kits, coils and premium e-liquids for retail and dispensary operations.
  • Vaporx offers the most current, highest quality products from the best-known brands, including KangerTech, eLeaf, Aspire, Pioneer4You, JoyeTech, Samsung. Vaporx acts as an extension to a client's purchasing department, providing the option to schedule regular product mix refresh for maximum sales.
  • GoldLine Hemp products are developed specifically for the convenience store market segment. GoldLine Hemp-only products are created without CBD, providing an alternative product line for consumers who are not ready to experience CBD products but still want to take advantage of this rapidly expanding class of products. GoldLine Hemp-only edible Hemp Gummies debuted at the National Association of Convenience Stores (NACS) Expo in Las Vegas in October 2018 and are now being distributed nationwide. The U.S. convenience store industry, with more than 154, 000 stores nationwide, serves 160 million customers daily and has sales that are 10.8% of the total U.S. retail and food service sales. Visit www.goldlinehemp.com for more information about GoldLine Hemp-only products.
  • Vapor Store Direct in Fort Lauderdale, Florida, is one of the largest vaporizer and e-liquid wholesalers in the United States. Vapor Store Direct stocks internationally elite brands, vaporizers, tanks/atomizers, coils, e-liquid, e-cigarettes, batteries, glass and accessories.

Management Team

CEO Kevin Frija is a veteran entrepreneur with nearly 30 years of experience in sourcing, manufacturing, supply chain management, marketing, advertising and brand licensing. In 2009, Frija became the president and chief executive officer of Vapor Corp., one of the first U.S. importers and publicly traded electronic cigarette companies. In 2016, Frija purchased the brands and wholesale business assets from Vapor Corp., which is now owned by VPR Brands. Under his leadership, VPR Brands is pivoting toward cannabis products which is increasing sales and profit margins.

Dan Hoff, chief operating officer, has worked in the vaporizer and e-cigarette industry, serving in various positions at Vapor Corp., including overseeing the financial management, accounting functions, supply chain management, product design and development, and key vendor relations. He has played a pivotal role in building and expanding the cannabis-based products division at VPR Brands, which includes a turnkey OEM vapor solutions program available to farmers, cultivators and extractors. Hoff received his bachelor's degree from the University of Miami School of Business.

VPR Brands, LP (VPRB), closed Wednesday's trading session at $0.0385, up 13.2353%, on 1,400 volume with 2 trades. The average volume for the last 3 months is 83,279 and the stock's 52-week low/high is $0.030999999/$0.119000002.

Recent News

chart

No Borders Inc. (OTC: NBDR)

The QualityStocks Daily Newsletter would like to spotlight No Borders Inc. (NBDR).

No Borders Inc. (OTC: NBDR) today announces the broadcast of its exclusive audio interview with NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community. The interview can be heard at http://nnw.fm/An8it. Also today, the company was featured in the 420 with CNW by CannabisNewsWire. On Friday, a bipartisan coalition of legislators from the House and Senate sent a letter to the Department of Justice requesting policy amendments, which would allow researchers to use marijuana bought from state-legal dispensaries for their studies on its benefits and risks.

No Borders Inc. (OTCQB: NBDR) specializes in the acquisition, creation and scaling of commercial products by utilizing cutting-edge technologies designed to reduce costs while increasing revenues and shareholder value. With active subsidiaries in healthcare, education, cannabidiol (CBD), finance and technology, No Borders is uniquely positioned to use its expertise to improve margins and add business lines within target verticals. No Borders is headquartered in Arizona with remote work resources in the U.S., South America, Asia and Europe.

Different by Design

Deeply experienced at actionable data compilation, analysis and utilization, No Borders believes that data utilization in a Web 3 ecosystem of predictive analytics, blockchains, consensus algorithms, IoT and 5G are vital keys to the future of disrupting global business.

The company leverages its technological talent and visionary approach alongside best-in-class branding, messaging and product teams to simultaneously deploy multiple vertical product offerings at the same time.

With resources around the world, No Borders operates as a 100% remote work, lean operating organization with a founding ideological focus on “Lifestyle by Design.” No Borders’ teams are built by allowing people to work when they want and from where they want as long as deliverables and results are achieved. This structure allows for strategic talent acquisition without the need for relocation or commuting; lowered operating and fixed costs; as well as improved morale and substantially increased staff productivity.

NBDR Companies

  • No Borders Dental Resources Inc. provides equipment and supplies to medical and dental professionals across the U.S. through the trade name, MediDent Supplies. MediDent has a strategic focus on expanding product portfolios and optimizing lifetime customer value while minimizing customer acquisition cost in the medical, dental and veterinary spaces.
  • No Borders Naturals is a purveyor of health and wellness products for active consumers and their pets. No Borders Naturals aims to be an industry leader in alternative wellness product offerings and is currently expanding its digital offering with impactful product up-sell opportunities such as a series of “Buy Two-Get One” on products on its 1000mg CBD tincture, collagen and retinol beauty cream.
  • No Borders Labs Inc. provides leading-edge tech tools to the No Borders family of companies along with building, testing and deploying technology solutions and products to the market while also offering consulting, architecture and software development services to external businesses looking to update their technology infrastructure for greater efficiency, security and transparency.
  • No Borders Funding Inc. provides internal capital and strategic funding options for the family of No Borders companies while actively engaging and networking to find, acquire, structure and deploy unique financial products, solutions and systems with traditional, distributed ledger and blockchain technologies.
  • No Borders Education Inc. provides internal staff training and strategic education tools for the No Borders family of companies while pursuing external revenue generating educational opportunities within the verticals for which No Borders deploys products, services or technologies.

 

Leadership

No Borders CEO Joseph Snyder is a serial entrepreneur whose experiences in real estate investment, financial services and digital strategy over the last 15 years provide a strong, grounded foundation for the structure and ideas outlined in the company’s strategic plan. He brings a unique set of long-term business experiences that provide No Borders with a clear “mile-high” view of the intricately linked systems and challenges associated with growing and scaling our vision.

COO Cynthia Tanabe, a licensed real estate agent/broker since 2004, has successfully built a highly respected investor and bank-focused real estate and property management firm in Arizona with tens of millions of dollars of properties owned and sold.

CTO Chris Brown has 14 years of experience in the IT industry ranging from full stack programming, hardware support, engineering and maintenance, to enterprise-level information system analysis, design, development and implementation. From his background in Air Force intelligence to earning dual B.S. degrees in computational mathematics and biochemistry from Arizona State University, Brown has been engrossed with technologies such as artificial intelligence, machine learning, and decentralized blockchain ledger systems and their connections with real world business applications.

Management is backed by an advisory board with a diverse range of expertise blockchain, brand development, specialty retail, branded consumer products, technology, marketing and other specialties pertinent to No Borders’ growth strategy.

No Borders Inc. (NBDR), closed Wednesday's trading session at $0.0191, up 27.3333%, on 127,006 volume with 8 trades. The average volume for the last 3 months is 66,328 and the stock's 52-week low/high is $0.007699999/$0.048799999.

Recent News

chart

InsuraGuest Inc.

The QualityStocks Daily Newsletter would like to spotlight InsuraGuest Inc..

InsuraGuest this morning announced that it is now live with Wisp Resort(R), a four-season ski, golf and mountain recreational destination resort in the mountains of western Maryland. The integration provides specialized insurance coverage that employs InsuraGuest’s proprietary InsurTech software as the first line of defense for the resort property and its guests. InsuraGuest Insurance Agency administers the product for hotels and vacation rental properties throughout the United States through Crum & Forster. To view the full press release, visit http://nnw.fm/2kh2Q.

InsuraGuest Inc. is a SaaS (Software-as-a-Service) company utilizing its proprietary flagship InsurTech software platform to provide specialized insurance products to end users in the business-to-business (B2B) and business-to-consumer (B2C) markets. The company’s first focus is on the B2B hotels and vacation rentals sectors, where its API integrates with the clients’ property management systems to offer guests a specialized guest protection policy. The platform and policy combination “InsurTech” product helps transfer the exposure to liability away from the client/property while guests benefit from potential accident and loss coverage during their stay.

InsuraGuest’s platform is currently capable of integrating with approximately 70 different hotel and vacation rental property management systems, giving it access to roughly 40,000 properties worldwide.

The company continues to pursue expansion opportunities and recently signed a Letter of Intent with a master general agent in the United Kingdom and Europe to distribute its platform and products to hotel and vacation rental markets in those regions, as well as plans to expand to Asia in 2020.

Protecting Guests, Enhancing Customer Experience

InsuraGuest is the first line of defense for both the property and the guest.

InsuraGuest is purchased by the hotel or vacation rental “property,” which offers the policy to each registered guest and its occupants for an additional fee. The specialized policy affords coverage for theft of personal property while in the hotel, as well as accidental medical expense and accidental death and dismemberment, up to the policy limits of $2,500 to $50,000.

Market Opportunity

The U.S. hotel industry generated more than $218 billion in annual revenues in 2018, an increase of $10 billion from the previous year, according to STR’s 2019 HOST Almanac. The European market is more than double the size of the U.S. market. According to Oxford Economics, there were 6.4 billion nights stayed in the world, with 2.6 billion hotel nights in Asia, 2.8 billion nights stayed in Europe, and 1.1 billion nights in the United States. Additionally, $100 billion was spent on vacation rentals in the United State alone, where there are approximately 4.5 million second homes are being managed by a third-party rental company.

With distribution in Europe and the United States, InsuraGuest’s demographics combined will total 3.9 billion nights stayed, and will more than double its vacation rental opportunities.

Within this burgeoning, high-demand industry is risk of liability to guest injury. For example, gym injuries are among the top five most common hotel accidents. Without proper hedges in place, the property may be liable in a personal injury claim or lawsuit.

Though the potential for accidents, slip and falls and mishaps can be widespread, it can be covered under the InsuraGuest Specialized Guest Protection Policy to provide guests a worry-free and enjoyable stay that potentially increases loyalty for the property.

Business Highlights

  • Targeting hotels and vacation rentals, a multi-billion-dollar industry
  • Providing the first line of defense in case of accident, loss or death
  • Expanding distribution reach with footing in European hotel and vacation rental markets
  • Expansion into Asia by 2020

Executive Team

Douglas Anderson, Chairman & Chief Executive Officer
Douglas Anderson has been a businessman in the real estate industry for nearly 30 years. His business expertise includes master planning and development implementation for larger-scale resorts, business parks and commercial developments across the USA and two provinces in Canada. His business endeavors include the founding of the 7th larger private equity fund in America focusing on multifamily and senior care (ROC Fund/Bridge IPG Fund). He serves as chairman/founder of a golf and winter sports ski holding company with operations in four major east coast markets and British Columbia, Canada.

Anderson earned a BS undergraduate degree in Consumer Studies with an emphasis in Architecture as an undergraduate at the University of Utah. He subsequently earned his Master’s in Business Administration. He also attended a three-year OPM Program a postgraduate business education at Harvard Business School in Boston. Anderson is an avid skier and outdoor enthusiast.

Charles James Cayias, President & Director
Charles James Cayias is also the president and owner of Charles James Cayias Insurance Inc. He is a third-generation insurance professional whose creativity and artistic vision have enabled him to establish a full-service agency combined with the personal service each client deserves. His outstanding people skills, honesty, integrity and fairness are evident by his loyal and growing clientele, the majority of which are referrals who become long-time customers and friends.

Cayias began his insurance career in the early 1970s and has been licensed since 1977. He is licensed in all 50 states and specializes in niche programs. He has extensive expertise in all aspects of the insurance industry including commercial insurance, employee benefits, workers’ compensation, professional liability, risk management and bonding.

Christopher J. Panos Vice President & Director
Christopher J. Panos is a highly competitive sales professional with over 15 years of territory manager sales experience and an award-winning record of achievements. He is exceptionally well organized with a proven work history that demonstrates self-discipline, superb communication skills, and the initiative to achieve both personal and corporate goals. Panos is successful in building relationships with a large network of industry professionals in order to grow and maintain new and existing business, exceed new sales objectives and provide in-depth product training to authorized dealers and sales personnel.

Alexander Walker III ESQ, Corporate Counsel & Director
Alexander Walker III ESQ has served as director of the company since September of 2018. He also has served as counsel to the company since July of 2018. Walker is an attorney and has been a member of the Utah Bar Association since 1987 and a member of the Nevada State Bar since 2003. His practice has involved general business litigation, in both federal and state courts, and transactional work, including securities offerings and registration, corporate formation and periodic reporting compliance. Walker has provided legal services to emerging businesses throughout his carrier and at times has served as an officer and board member as well as legal counsel public companies. His duties as legal counsel for a public company engaged in the business of ownership and operation of coal-producing properties in the western United States included oversight of corporate-related legal matters including securities reporting, corporate compliance, federal and state mining regulation, and employment law oversight. He also has served as the chair of the Mining Committee of the Energy, Natural Resources and Environmental Law Section of the Utah State Bar, a member of the board of directors of the South East Utah Energy Producers Association, the co-chair of the board of the Western Energy Training Center, a board member of the Utah Supreme Court Committee to Review the ABA Recommendations Regarding the Office of Professional Conduct, and a board member of the University of Utah Crimson Club.

Roger Bloss, Corporate Consultant & Board Advisor
Roger Bloss joined InsuraGuest in August of 2019 to advise the company and its board on hotel transactions, contributing his knowledge from more than 40 years in the hospitality industry. Bloss previously served in executive positions with several major hotel franchise companies and in 1996 founded Vantage Hospitality Group hotel brands. Under his leadership, Vantage became a Top 10 global hotel company and made the Inc. 500/5000 list of Americas’ fastest-growing private companies for eight straight years. Bloss was named Lodging Magazine’s “Innovator of the Year” in 2006 and 2010, and in 2009 earned a spot on HSMAI’s “Top 25 Extraordinary Minds in Sales and Marketing.” Bloss joined Red Lion Hotels Corporation (RLHC) in September 2016 in conjunction with the acquisition of Vantage.


Recent News

chart

Youngevity International, Inc. (NASDAQ: YGYI)

The QualityStocks Daily Newsletter would like to spotlight Youngevity International, Inc. (YGYI).

Youngevity International, Inc. (NASDAQ: YGYI) was featured today in the 420 with CNW by CannabisNewsWire. On Friday, a bipartisan coalition of legislators from the House and Senate sent a letter to the Department of Justice requesting policy amendments, which would allow researchers to use marijuana bought from state-legal dispensaries for their studies on its benefits and risks. The legislators were led by Rep. Harley Rouda (D-CA) and Sen. Brian Schatz (D-HI). In the letter, they cited federal health agencies’ feedback where they said that research on marijuana is inhibited by the existing restrictions on cannabis.

Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that includes e-commerce and the power of social selling. Among the Top 100 Global Direct Selling Companies, Youngevity offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, and a range of innovative services. Created through the 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company, today’s Youngevity International Inc. is a virtual worldwide Main Street of products and services under one corporate entity that supports a healthy and empowered lifestyle.

Youngevity International is dedicated to improving lifestyles through the universal desires of vibrant health and flourishing economics. Catering to health-conscious consumers, Youngevity believes that combining the best of the direct selling industry with the fundamentals and capabilities of a traditional business model will maximize shareholder value. The company’s Nutritional, Lifestyle and Telecommunications products and services are distributed through a global network of Preferred Customers and Distributors.

Youngevity’s wholly owned CLR Roasters LLC business line offers quality branded and private label coffee to retail stores, office coffee services, hospitality, food services, distributors, convenience, petrol stores and vending businesses. Today, CLR Roasters is the largest coffee provider for cruise lines in North America and the second largest roaster in the state of Florida. Producing a consistent premium product with superior taste, CLR Roasters has earned numerous certifications that demonstrate the company’s commitment to the craft of providing the highest quality coffee products using the best practice standards available.

Youngevity, operating in the direct-selling channel, is rapidly expanding its product and distributor base through acquisitions and mergers under an innovative concept called “the Network Cloud” that provides other direct selling companies with a home base. The company’s YoungevityGO2 mobile distributor app, a new technology-driven web platform supporting expansion of global e-commerce and social selling platforms, is available on Google Play and the App Store. In addition to the Network Cloud concept, Youngevity International owns CLR Coffee Roasters which operates a traditional coffee roasting business offering a JavaFit® gourmet product line that vertically integrates with Youngevity and its growing network of direct marketers.

Youngevity International offers more than 1,000 high quality, technologically advanced products under the following categories:

  • Health and Nutrition
  • Home and Family
  • Food and Beverage
  • Spa and Beauty
  • Fashion
  • Essential Oils
  • Photo and scrapbooking
  • Services for Home and Business

Youngevity International Inc. has compiled a best-in-class management team with a strong track record of success in private and public companies. Steve Wallach, CEO, has nearly two decades of sales and network marketing experience and has successfully guided Youngevity International Inc. to become an international, publicly-traded direct marketing company positioned for worldwide growth. Dave Briskie, president and CFO, has shepherded the company’s development into a fully vertical coffee roasting and distribution company that owns the direct marketing brand JavaFit® and the retail brand, Café La Rica.

Youngevity has also attracted a stunning group of Brand Evangelists who endorse its products. Among these are actress, author and well-known health and wellness activist Marilu Henner; former NBA basket player, Mike “Stinger” Glenn; former NFL wide receiver Drew Pearson; “Greatest Natural Bodybuilder in the World” Gene Nelson; and WNBA champion, Olympic gold medalist Delisha Jones.

Youngevity International, Inc. (NASDAQ: YGYI), closed Wednesday's trading session at $3.94, off by 0.755668%, on 42,858 volume with 339 trades. The average volume for the last 3 months is 43,014 and the stock's 52-week low/high is $3.70000004/$9.27999973.

Recent News

chart

Sigma Labs Inc. (NASDAQ: SGLB)

The QualityStocks Daily Newsletter would like to spotlight Sigma Labs Inc. (SGLB).

Sigma Labs Inc.’s (NASDAQ: SGLB) exclusive, in-process quality-control platform for metal-additive manufacturing was featured at the SGLB booth at Formnext 2019, the industry’s premier global conference held November 19-22, 2019, in Frankfurt, Germany. SGLB, the leading developer of quality assurance software for the commercial 3D metal-printing industry, participated at the event, where more than 850 exhibitors and almost 35,000 attendees gathered to view an impressive display of digital manufacturing capabilities. To view the full article, visit http://nnw.fm/BnVR6 Also today, NetworkNewsWire released a report on the company detailing how SGLB enables operators of machines making 3D metal parts to offset emerging quality problems, sustain part quality and avoid rejects through its in-process quality-assurance software. To view the full article, visit http://nnw.fm/BnVR6.

Sigma Labs Inc. (SGLB) is the only provider of in-process quality-assurance software to the commercial 3D printing metal industry that enables operators of machines making 3D metal parts to offset emerging quality problems, sustain part quality, and avoid rejects. Sigma’s software is the singular solution that enables both real-time, in-process detection of quality control manufacturing irregularities for critical metal parts and then provides the operator the actionable information needed to adjust and mitigate the developing anomaly. Sigma Labs’ software represents a paradigm shift in the quality control process for the manufacture of 3D printed metal components. The nascent 3D metal printing industry is on the verge of radically altering the speed and technical complexity of manufactured parts. Further, it makes possible just-in-time availability of critical components – all at reduced cost, time, waste and weight. 3D printing, heralded as the fourth industrial revolution in manufacturing, will only truly surpass traditional techniques when the additive manufacturing industry moves from “post process” quality control to “in process” quality assurance.

For the industry to move from prototype manufacturing of critical components to economically viable commercial production, the 3D metal printing industry must find ways to dramatically increase production speed and quality yields, and to dramatically decrease the excessive cost of quality control. To achieve these prerequisites and move 3D metal printing into the mainstream, parts must be inspected and certified during the manufacturing process rather than after. Parts in the production process that are developing signs of quality control problems must be identified in real-time and alerts must be issued. The problem, along with the solution, must then be communicated to the machine operator to implement repairs.

Revolutionizing Additive Manufacturing

Sigma Labs, with its PrintRite3D® brand, has established a new benchmark in the development and commercialization of real-time computer aided inspection (“CAI”) solutions. Sigma Labs resolves the major roadblocks and costly quality control challenges that impede the 3D manufacture of precision metal parts. The company’s breakthrough computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance during production, uniquely allowing errors to be corrected in real-time.

Sigma Labs was founded in 2010 by a team of Los Alamos National Labs scientists and engineers to develop and commercially license advanced metallurgical products for the military ordinance, dental implants, and then for additive manufacturing (3D printing). After assessing 3D metal printing technology and the costly, inconsistent quality control issues, Sigma Labs concluded that the enormous potential of 3D metal printing could only scale up if in-process quality-assurance tools were developed to observe, manage and control the manufacturing complexities in such a manner that reliability and repeatability of very high precision quality metal parts could be achieved in the process. Sigma Labs’ patented and third-party validated software has achieved these objectives and now delivers the critical elements needed to unleash the promise of 3D metal printing.

Sigma Labs’ products and services are engineered, manufactured and qualified for use in the highly demanding and hyper precise production environments of the aerospace, defense, transportation, oil and gas, biomedical and other precision-dependent industries.

The Challenge

Additive metal manufacturing combines multiple processes and parts into one single 3D printed part. Due to variances in the additive manufacturing process, parts of consistent quality currently can’t be reliably produced in either large or small quantities without substantial postproduction inspection and rejection costs. Parts are inspected after production using CT scans and other means, so the manufacturer doesn’t know until the very end which of the finished parts meet design specifications. This means lost time, lost profits and inability to economically scale up production.

Innovative Approach

Sigma Labs solves this problem with its patented, in-process quality control technology that informs operators and engineers how to improve both the manufacturing process and quality by capturing meaningful data about inconsistencies in real-time. Sigma Labs is also partnering with OEMs, working toward the visionary introduction of revolutionary closed-loop control that will bypass the machine operator and automatically make in process corrections by reducing machine variations.

Sigma Labs’ next generation technology gives manufacturers the ability to make fast, virtual real-time adjustments so that each finished part is uniform and within critical specifications, thereby improving production quality, decreasing end-users’ risks and waste, and increasing profits and speed to market. Sigma Labs’ PrintRite3D® IPQA Software monitors and assesses the quality of each production part in the 3D additive manufacturing process – layer by layer, and in real-time. This has never been available until now.

Sigma Labs maintains a strong intellectual property portfolio consisting of trade secrets, process know-how and 34 patents either granted, pending or awaiting pre-publication around the globe. These patents encompass the fundamental technologies underlying Sigma Labs’ melt pool process control, data analytics, anomaly detection, signature identification, and future “closed-loop control” of 3D metal printing.

Market Opportunity

Providing advanced quality assurance software to the commercial 3D printing industry is currently a $1.4 billion addressable market expected to grow to $3.9 billion by 2023. Integrating Sigma Labs’ groundbreaking software helps arm the industry with a necessary catalyst to help enable and optimize the fourth industrial revolution in manufacturing.

Sigma Labs’ global client base includes 23 installations across 19 different users. Tier-1 OEM enterprises and end-users such as Siemens, Honeywell, Pratt & Whitney and others are currently evaluating PrintRite3D® for production lines.

Management Team

John Rice, CEO and chairman of the board of directors, has extensive experience as a CEO, lead negotiator, turnaround expert, business financier and crisis management executive/consultant. Prior to becoming chair and CEO of Sigma Labs, he was the CEO of a successful turn-around of a Coca-Cola Bottling Company. Rice has led a variety of companies in diverse business sectors and worked on a host of products and technologies including design and manufacture of high-end jet engine test equipment for the U.S. Airforce, chaff dispensers for F16s, software for modeling naval exercises, software for controlling warehouse distribution systems, medical radioisotopes, cancer detection, and cybersecurity. He is an honor’s graduate of Harvard College.

Darren Beckett, CTO, has over 20 years of experience in the semiconductor industry, including Intel Corporation, where he held various technical and managerial positions. His expertise in process engineering for advanced manufacturing technology includes statistical process control for fabrication of semiconductor devices.

CFO Frank D. Orzechowski also serves as treasurer, principal accounting officer, principal financial officer and corporate secretary. He has more than 30 years of distinguished financial and operational experience. Orzechowski began his career at Coopers & Lybrand in 1982, received his CPA certification in 1984, and received his Bachelor of Science in Business Administration with a major in accounting from Georgetown University in 1982.

Ronald Fisher, vice president of business development, is leading the commercialization of PrintRite3D® 5.0. Fisher is a mechanical engineer with hands-on experience in quality, manufacturing and product development. He has distinguished himself as a lead sales and marketing officer as well as a chief operating officer most recently before joining Sigma in technology startup that grew from market entry to successful exit by merger-acquisition.

Sigma Labs Inc. (SGLB), closed Wednesday's trading session at $1.03, off by 2.3697%, on 83,354 volume with 242 trades. The average volume for the last 3 months is 189,553 and the stock's 52-week low/high is $0.451099991/$2.46000003.

Recent News

chart

Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF)

The QualityStocks Daily Newsletter would like to spotlight Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF).

Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) was featured today in a publication from CBDWire, examining how, with demand for the hemp extract at an all-time high, tons of CBD sellers have flooded the market looking to cash in on the insane demand.

Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. The company’s cannabidiol (“CBD”) yeast-based biosynthesis program produces a high yield, ultrapure, low-cost and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.

The company is headquartered in Calgary, Alberta, Canada.

Biosynthesis Platform

Willow’s proprietary yeast-based lab strains produce CBD, tetrahydrocannabinol (“THC”), and cannabigerol (“CBG”), as well as certain minor and novel cannabinoids.

The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by Chief Scientific Officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional non-pathway, yet commercially-essential, accessory genes.

Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell “factory.” This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days – far less time than traditional plant-based extraction methods.

Willow anticipates its technology can be scaled to produce hundreds of kilograms per batch of cannabinoid API at less than $1,000 per kilogram, thus costing approximately 60% less than current chemical synthesis methods and 90% less than conventional plant-based extraction methods.

World-Class Collaboration

Willow and Noramco Inc., the world’s largest producer of high-quality synthetic cannabinoid APIs and other controlled substance APIs for the pharmaceutical and healthcare industry, have an exclusive, worldwide Joint Development Agreement (“JDA”) to design a yeast-based biosynthesis platform for the production and distribution of a highly pure CBD isolate.

The mutually exclusive agreement calls for Willow to be responsible for optimizing yeast strains in a biosynthetic process to generate ultrapure CBD at high yield and substantially lower cost compared to current methods. Noramco will leverage its decades of experience in producing and delivering CBD and pharmaceutical APIs by being responsible for the scale-up, regulatory submission, marketing and distribution of products manufactured under the JDA.

Each company will invest comparable funds, will retain the intellectual property associated with their respective scopes of work and share equally in gross profits from sales of products manufactured under the JDA.

Market Opportunity

The agreement with Noramco (http://nnw.fm/Mz1vW) addresses the increasing demand for CBD-based APIs and other CBD-infused products by pharmaceutical, nutraceutical, consumer packaged goods, beverages and other industry sectors.

The U.S. market potential of cannabinoids is significant, with industry analysts projecting $50 billion in cannabinoid-based pharmaceutical sales and $16 billion in CBD consumer goods retail sales by 2025. As of June 2019, 34 U.S. states and the District of Columbia, Guam, Puerto Rico and U.S. Virgin Islands have legalized cannabis for medical use. Another 13 states and territories have approved recreational cannabis for adult use while other states are considering similar measures.

The cannabinoid API market continues to evolve with CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as post-traumatic stress syndrome, epilepsy, Parkinson’s disease, chronic pain, schizophrenia, cancer treatments and other challenging unmet medical conditions.

Capitalization

Willow is fully funded after raising $29 million via private placement and $8 million in exercised warrants by Tuatara Capital Fund II, L.P. Proceeds of the funding will be used to enhance the existing laboratory space in Calgary and Vancouver, Canada, and in San Francisco, California. The company anticipates exiting 2020 with $15.8 million in cash.

Leadership

President and CEO Trevor Peters is an experienced executive who co-founded four startup companies in the past 15 years. He has raised over $1 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4 billion on sale. Mr. Peters previously was chief financial officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.

Chief Financial Officer Travis Doupe has over 18 years of experience in financial leadership roles, principally in the international oil and gas industry, where he provided corporate strategic direction while overseeing all aspects of financial operations. Mr. Doupe is the treasurer and a member of the board of directors of the Canada Council for the Americas – Alberta and holds a CA-CPA designation and earned a bachelor’s degree in management from the University of Calgary.

Dr. Peter Facchini, Chief Scientific Officer, has been professor of plant biochemistry in the Department of Biological Sciences at the University of Calgary since 1995. He is recognized internationally as a leader in plant specialized metabolite biosynthesis. Dr. Facchini is the Canada Research Chair in Plant Metabolic Processes Biotechnology and has published more than 150 research papers and scholarly articles. Dr. Facchini received a PhD from the University of Toronto and conducted postdoctoral research at the University of Kentucky and Université de Montréal.

Dr. Joseph Tucker, Executive Chairman of the Board of Directors, holds more than 20 issued or pending patents and is a member of the Board of Directors of BioAlberta. He has extensive senior leadership experience in multiple public and private biotech companies. Dr. Tucker received a PhD in biochemistry and molecular biology from the University of Calgary.

Willow Biosciences Inc. (OTCQB: CANSF), closed Wednesday's trading session at $0.46, off by 4.1866%, on 3,000 volume with 1 trade. The average volume for the last 3 months is 7,212 and the stock's 52-week low/high is $0.423999994/$2.1775.

Recent News

chart

MCTC Holdings Inc. (OTC: MCTC)

The QualityStocks Daily Newsletter would like to spotlight MCTC Holdings Inc. (MCTC).

MCTC Holdings Inc. (OTC: MCTC) was featured today in a publication from HempWireNews, examining how hemp is an extremely versatile crop. It is used to make paper, textiles, biodegradable plastics and fuel among a plethora of applications. Not to mention the extremely useful and popular hemp extract cannabidiol (CBD). However, one of hemp’s most exciting applications is in construction.

MCTC Holdings Inc. (OTC: MCTC) is an innovator in the field of cannabinoid nanoparticles and infusion technologies with several important cannabinoid patents filed and an active research and development program underway. The company was reorganized during June of 2019 and announced its intent to enter the cannabis sector and change its corporate identity to Cannabis Global Inc. The company is headquartered in Los Angeles, California.

With the hemp and cannabis industries rapidly expanding in terms of market size, acceptance and number of market participants, MCTC plans to concentrate its efforts on the middle portions of the hemp and cannabis value chain. The company is actively pursuing R&D programs and productization of advanced cannabinoid delivery systems, based on solid polymeric nanoparticles and fibers. These technologies hold the promise to revolutionize the science of cannabinoid bio-enhancement for use in foods, beverages, consumer products and in transdermal applications. Because of nanoparticles’ ability to be quickly absorbed into the bloodstream, nanotechnology has been utilized in the food and drug industry for some time and has the potential for tremendous growth in the cannabis industry (http://nnw.fm/v6RQ6).

Cutting-Edge Technology

MCTC is at the cutting-edge of the cannabis industry’s trends with its emphasis on polymeric nanotechnology. This is not to be confused with the more basic oil-in-water nano-emulsions currently marketed to the food and beverage industry. The company’s polymer-based particles offer significant loading of active ingredients and unmatched flexibility and customization, allowing for myriad combinations of cannabinoids with unique performance characteristics. MCTC believes polymeric nanotechnology particles will be a critical technology area for the cannabinoid formulation marketplace.

The company continues to build its R&D program, specifically researching the development of improving methods to make cannabinoids available to living systems. Instrumental in the research program is the development of novel polymeric nanoparticles and nanofibers. These have the potential to elevate the potential of cannabinoid products in the following ways (http://nnw.fm/cK3Bl):

  • Significantly improving bioavailability
  • Allowing for ultra-high loading rates
  • Enhancing customization of cannabinoid combinations
  • Improved dosing precision
  • Providing more control in release parameters

MCTC leadership understands the importance of developing intellectual property (IP) in the ever-evolving cannabis industry. A recent Forbes article described IP as “critical for creating true differentiation between companies and their product and service offerings” (http://nnw.fm/57Fjh). Recognizing the importance of IP, MCTC has been consistent in its application for patents to protect its innovative nanotechnology applications.

Patents

MCTC has now filed four patents on its cannabinoid delivery technology systems:

  • The company first collaborated with Cannabis Nanosciences Inc. on technologies. This became the basis for its first patent filing on an innovative edible dissolvable film for cannabinoid ingestion.
  • Its second patent filing for cannabinoid nanoparticles combined TPGS, a water-soluble form of vitamin E.
  • Its third patent filing involved a unique 4th dimension, 3D printed cannabinoid delivery system for beverages.
  • Its fourth patent, considered its most significant, broadly covers many aspects of nanoparticles and nano fibers comprising one or more cannabinoids disposed at least partially within a water-soluble medium.

Collaborations

MCTC collaborated with Marijuana Company Inc. (OTCQB: MCOA) subsidiary hempSmart Inc., under a hemp extract and CBD product supply agreement wherein hempSmart will utilize its extensive network of marketing partners to market MCTC’s powered drink mixes and other CBD edibles online. These products are designed for the dry beverage and edibles sector and will be supplied by MCTC. They incorporate the company’s patent-pending cannabinoid infusion technologies and will be trademarked as Hemp You Can Feel (TM) and Gummies You Can Feel (TM).

Leadership

MCTC CEO and chairman Arman Tabatabaei boasts 15 years of management and operations experience and is considered an expert at data collection and analysis relative to resource management, risk forecasting, and profit and loss management. He has acted as a consultant with Cannabis Strategic Ventures (OTCQB: NUGS) and played an instrumental role in improving operations at Sugarmade Inc. (OTCQB: SGMD) relative to the company’s hydroponic growth supplies initiatives.

MCTC founder and director Robert Hymers also brings a seasoned perspective, having had significant experiences in the cannabis industry and as a financial executive and consultant. He is the managing partner of Pinnacle Tax Services in Los Angeles and was previously CFO and director of Marijuana Company of America Inc. (OTC: MCOA). He is currently a member of the Strategic Advisory Board at Massroots Inc. and acts as a consultant to both Cannabis Strategic Ventures Inc. and Sugarmade Inc. Hymers’ background in tax accounting, auditing, SEC reporting, mergers and acquisitions, and corporate finance has immense value in his current position at MCTC Holdings.

MCTC Holdings Inc. (MCTC), closed Wednesday's trading session at $0.39, off by 10.3448%, on 2,867 volume with 3 trades. The average volume for the last 3 months is 12,594 and the stock's 52-week low/high is $0.075000002/$3.00.

Recent News

chart

Wonderfilm Media Corporation (TSXV: WNDR) (OTC: WDRFF)

The QualityStocks Daily Newsletter would like to spotlight Wonderfilm Media Corporation (OTC: WDRFF).

When My Big Fat Greek Wedding landed in theaters nearly 20 years ago, the inauspicious film centered on ethnic minority tropes was met by underwhelming praise from reviewers, one of whom noted the “slight but agreeable comedy” … “lacks cinematic flair. It looks (http://nnw.fm/BwR8k) more like a film designed for the small screen. But … it has a good-natured personality.” Thanks to the mutable nature of the Internet, a modern updating of the review adds that the film “became an unexpected theatrical hit,” gaining a reputation as the second highest-grossing American romantic comedy in film history (http://nnw.fm/Cr59Y). The movie parlayed the production company’s $5 million budget into about $250 million (inflation-adjusted to $368.7 million) in revenues, and in the process helped establish a business model that British Columbia-based film production house Wonderfilm Media Corporation (TSX.V: WNDR) (OTCQB: WDRFF)is taking all the way to the bank.

Wonderfilm Media Corporation (TSXV: WNDR) (OTC: WDRFF) main business is the worldwide production of high-quality feature films and episodic television. The Wonder?lm team includes Hollywood veterans who have packaged, produced and delivered several profitable recent films, including “BlacKkKlansman,” “Get Out” and “The Hurt Locker.” Having these individuals on the Wonderfilm team demonstrates the company’s proven access to Academy Award-quality films and upside.

Wonder?lm maintains a continuing $58 million annual production slate to meet the constant and growing need for content worldwide. The company’s risk-averse production process results in predictable and consistent revenue streams.

Soaring demand for content from streaming providers is fueling industry growth. The global media and entertainment market is expected to grow from $1.9 trillion in 2017 to $2.4 trillion in 2022, a five-year CAGR of 4.4%.

The company recently formed Wonderfilm Global, an international film and television sales and distribution joint venture that is expected to generate significant incremental revenue.

Wonderfilm has strong relationships throughout the entertainment industry, which enables cost-effective production budgets and in-demand content creation.

Management Team with Proven Track Records

Kirk Shaw: Over 240 movies and seven television series to his credit. Headed up Canada’s largest independent film and television production company, attaining $100 million revenue two years straight with 8% EBITDA.

Dan Grodnik: Founded Mass Hysteria Entertainment, a publicly traded company, and became its chairman/CEO. Produced over 50 feature films, including “Bobby,” the 2006 Robert Kennedy biographic film.

Shaun Redick & Yvette Yates: $300 million+ USD total production budgets to date with a combined 175 award wins/355 nominations, including 10 Oscar nominations. In 2017 and 2018, they produced two of the most successful Hollywood films of those years: “Get Out” ($255 million USD gross revenue) and “BlacKkKlansman” ($100 million USD gross revenue). Scheduled to produce two to three films per year for Wonderfilm, with the first release slated for October 2020. Committed to the 4% challenge to give more women and women of color the opportunity to direct.

Jeff Bowler: 2017 Emmy Award-winning producer. Vice president of acquisitions and production for The Exchange, one of the top film sales and finance companies in the world. Bowler is the executive for Wonderfilm Global distribution.

Bret Saxon: Through his company, TMP Inc., Saxon created M&A deals worth over US$750 million across 113 countries. Produced several feature films and made-for-television movies, including Wonderfilm’s 2019 movie “Zombie Tidal Wave” for NBC/Universal’s SYFY.

17-Title Movie Slate — Greenlit

Wonderfilm currently has 17 films greenlit with combined budgets totaling $58 million. Wonderfilm production stars include: John Travolta, Nicolas Cage, Guy Pearce, Ryan Phillippe and Anne Heche, to name a few.

Some of the company’s most notable greenlit projects include the horror film “Amityville 1974,” slated for theatrical release in October 2020, and the action film “Inside Game” starring Tyrese Gibson, which will be released to theaters in fall 2020.

The company is also actively developing a number of other new IP projects, including a dramatic biographic feature titled “Life and Times of Steve McQueen,” a film adaptation of the bestselling novel “Merchant of Death” and a television series headed by “CSI: Crime Scene Investigation” creator Anthony Zuiker.

 

Potential for Breakout Success

Wonderfilm movies have the potential for millions of dollars in revenue from the kind of breakout success generated by films like “Saw” and “Get Out,” which would propel Wonderfilm and its revenue streams to a new level. Wonderfilm has several potential breakout films in its development/production queue.

Note: Potential breakout films are not factored into company’s revenue projections.

Base Hits and Home Runs

In tandem with its slate of high-profile films, Wonder?lm continues to finance, produce and deliver many profitable low-risk, lower-budget films that are base hits. Shaun Redick is a home run hitter, and his upcoming Wonderfilm projects are anticipated to be home run hits for the company, while base hits such as “Zombie Tidal Wave” provide a consistent source of revenue.

Recent Industry Breakout Films Include:

  • SAW – $1.2 million budget = $103.9 million in sales
  • Pulp Fiction – $8 million budget = $212 million in sales
  • My Big Fat Greek Wedding – $5 million budget = $250 million in sales
  • Lost in Translation – $4 million budget = $120 million in sales
  • Get Out – $4.5 million budget = $255.5 million sales (Shaun Redick)

Note: Revenue from most of Wonderfilm’s current slate will be recorded on the books in 2020 or 2021.

Recent Wonderfilm Releases

  • Aug. 17, 2019: Co-produced with NBC/Universal, “Zombie Tidal Wave” premièred on the SYFY channel to strong ratings.
  • Aug. 29, 2019: “The Fanatic” starring John Travolta opens in U.S. theaters.
  • Sept. 5, 2019: “Tammy’s Always Dying” premiers at Toronto Film Festival.
  • Nov. 8, 2019: “Primal” starring Nicolas Cage opens in U.S. theaters.

Wonderfilm Global Distribution

At the 2019 Cannes Film Festival, Wonderfilm officially launched Wonderfilm Global, a new film, television and media foreign sales/distribution joint venture with 101 Films and Paul McGowan.

Wonderfilm acquired 51% ownership in the joint venture structure and immediately began attaching its own productions to Wonderfilm Global. The joint venture represents a significant opportunity for Wonderfilm, changing how the company does business.

The intention behind Wonderfilm Global is to keep distribution margins in-house that previously went to other companies. Since most Wonderfilm movies are relatively low-risk and easy to sell because they feature desirable cast and genre, third-party distribution companies were previously earning approximately 10%, plus expenses, on Wonderfilm movies without any level of risk. Now, revenue is generated through presales of Wonder?lm projects and, at times, third-party films. The average Wonder?lm movie is pre-sold for $5million, garnering $500,000 to $750,000 per sale as a commission. These commissions now stay in-house with Wonder?lm Global, and the company expects to sell 10 to 12 third-party films between fall 2019 and fall 2020, generating roughly $6 million in commission income.

A further revenue source is generated from theatrical sales through a 50/50 upside split once the minimum sales threshold is met.

Wonder?lm Global has offices in Vancouver, Beverly Hills, London, Ireland, Seoul and China.

Wonderfilm Business Model

Wonderfilm productions are structured to begin generating a return to the company as soon as the camera starts rolling.

Return Before a Film is Delivered: Producer fee line items are included in each production budget. These range from $50,000 to $500,000, depending on the total budget, and are paid to Wonderfilm most commonly on the first day of principle photography.

Distribution: Wonderfilm Global charges sales and distribution fees within each production budget to cover its presale costs.

Note: Wonderfilm’s productions are all structured to minimize risk by matching budget to funds available.

Return After a Film is Delivered: Unsold presale territories are countries or territories left off of a film’s presale list, either for strategic reasons or because the broadcaster/distributor is waiting to see the completed film. These outside-the-budget distribution sales become Wonderfilm profit centers.

Sales overages once contracted presale threshold is surpassed.

The company’s film library grows with each new production, adding to future sales revenue. Depending on the agreement, exploitation rights for future worldwide sales return to Wonderfilm four or seven years after delivery. As of October 2019, Wonderfilm’s growing film library comprises 18 titles for future exploitation.

Note: The nature of the film business is that box office revenue lags production up to a couple of years.

$50 Million Wonderfilm Production Fund (WPF):

Wonderfilm is in the process of raising $50 million to establish a Wonderfilm Production Fund (WPF). WPF is designed to consolidate traditional production financing models into a single diversified, asset-backed debt instrument.

The WPF is a highly specialized investment vehicle with noncorrelated market returns normally reserved for institutional banks and specialty lenders, and it would pay 8% interest directly from each Wonderfilm movie or series budget and not from corporate funds. These same interest payments are already added to each production budget, as the company currently closes a separate financing for every film. The WPF would significantly streamline Wonderfilm’s production rate, adding revenue more quickly and broadening the yearly production slate.

For fund investors, the WPF is a dedicated production-financing vehicle designed to offer a risk-moderated approach to investing in film finance. The managed process provides structure and reassurance that are normally experienced only when working with an institutional lender that has a dedicated staff and resources.

All projects being financed are for Wonderfilm productions, with the fund collateral fully secured by receivables, including presale contracts, government incentives, or a guarantee from Wonderfilm for any unsecured amounts as may be permitted.

Wonderfilm Media Corporation (OTC: WDRFF), closed Wednesday's trading session at $0.09, off by 2.7027%, on 563 volume with 4 trades. The average volume for the last 3 months is 42,492 and the stock's 52-week low/high is $0.075099997/$0.462000012.

Recent News

chart

Endonovo Therapeutics Inc. (ENDV)

The QualityStocks Daily Newsletter would like to spotlight Endonovo Therapeutics Inc. (ENDV).

Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today it has determined to effect a 1-for-1,000 reverse stock split of the Company’s issued common shares. The reverse stock split will take effect, and the Company's common stock will begin trading on a split-adjusted basis on the OTCQB, after the reverse split has completed FINRA review under the existing ticker symbol "ENDVD".

Endonovo Therapeutics Inc. (ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical™ Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.

In accord with its mission to transform the field of medicine through innovation, Endonovo’s bioelectric Electroceutical™ devices harness bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur. Endonovo’s current portfolio of commercial-stage devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.

Flagship Therapy

SofPulse® Electroceutical ™ Therapy is an easy-to-place, non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery. Used as a stand-alone therapy or integrated into any treatment protocol, SofPulse®’s targeted pulsed electromagnetic field (tPEMF) transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. The low levels of electromagnetic fields are completely safe and are 1000 times lower than those emitted by a mobile phone. 

Because SofPulse® lessens the pain of post-surgical recovery, the patient requires far less prescription medications, thereby minimizing or eliminating the adverse side effects of narcotics and anti-inflammatory medication. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. Patients with less pain and medication may move around sooner, which further stimulates the body’s natural response to healing.

Certifications

Endonovo’s Electroceutical™ Therapy is cleared by the U.S. Federal Drug Administration (“FDA”) for the palliative treatment of pain and post-surgical edema (swelling) and is CE-marked in the European Economic Area (“EEA”) for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”) has also certified Electroceutical™ Therapy for the treatment of chronic wounds.

Management

Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.

Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy. 

Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.

Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.

Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.

David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.

Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.

Steven C. Levin, M.D., Scientific Advisory Board Member
Dr. Steven C. Levin is the regional medical director at Johns Hopkins School of Medicine and medical director at Howard County General Hospital in Columbia, Maryland. Additionally, he is an assistant professor at Johns Hopkins School of Medicine, Department of Anesthesiology. Dr. Levin is currently the co-chair of the Opioid Stewardship Clinical Community as well as a clinical design team leader of the Musculoskeletal Center in the Johns Hopkins Health System. Additionally, Dr. Levin has previously served on the medical school facility at Yale University and at University of Pittsburgh Medical Center. Dr. Levin received his undergraduate degree from University of Pennsylvania and medical degree at the University of Pittsburgh. He completed his residency and fellowship at the University of Pittsburgh Medical Center. His membership in professional and scientific societies has included the American Society of Anesthesiology, American Pain Society, American Society of Regional Anesthesia, Society in Anesthesia and International Association for the Study of Pain.

Peter Novak, M.D., Ph.D., Scientific Advisory Board Member
Dr. Peter Novak is the director of the Autonomic Laboratory at the Department of Neurology, Brigham and Women’s Hospital in Boston, Massachusetts. He is a board-certified neurologist and a board-certified autonomic specialist. He is a member of the American Academy of Neurology, American Autonomic Society and the Autonomic Board of United Council for Neurologic Subspecialties. Dr. Novak graduated from medical school in Bratislava, Slovakia, and completed his neurology residency at Ohio State University. He also completed postdoctoral studies focusing on cardiovascular and autonomic research at Charles University (Prague) the University of Montreal, McGill University (Montreal) and the Mayo Clinic. He has special interests in autoimmune, small fiber and autonomic neuropathies, autoimmune, postural orthostatic tachycardia syndrome and multiple system atrophy. He has written over 70 papers and presented at numerous conferences.

Geoffrey Abrams, M.D., Scientific Advisory Board Member
Dr. Geoffrey Abrams is an assistant professor of orthopedic surgery at the Stanford University School of Medicine and the director of sports medicine for Stanford’s varsity athletes. He specializes in orthopedic sports medicine and arthroscopy of the shoulder, knee and elbow as well as upper extremity joint replacement surgery. Dr. Abrams is a member of the American Academy of Orthopedic Surgeons (AAOS) and the American Orthopedic Society for Sports Medicine (AOSSM), among others, and currently serves as assistant team physician for the NFL’s San Francisco 49ers as well as head team physician for a number of Stanford University varsity athletic teams. He is actively involved in research focusing on the role of inflammatory mediators, and microRNA in particular, on cartilage and tendon damage. Dr. Abrams received his undergraduate degree from Stanford University and his doctorate of medicine from the University of California – San Diego. He completed his residency in orthopedic surgery at Stanford University and went on to receive additional training in Orthopedic Sports Medicine and Shoulder Surgery at Rush University Medical Center in Chicago, Illinois. Dr. Abrams has authored or co-authored over 60 peer-reviewed scientific articles, over 20 book chapters, has presented original research at numerous national and international scientific meetings, and serves as a reviewer for numerous sports medicine scientific journals.

Dr. William Li, Scientific Advisory Board Member
Dr. William Li is CEO and co-founder of the Angiogenesis Foundation. He trained in the lab of Dr. Judah Folkman, pioneer of the angiogenesis field, and has been actively engaged in angiogenesis research and clinical development for 30 years. Under Dr. Li’s leadership, the foundation has developed a unique social enterprise model based on value-creating collaborations with leading biopharmaceutical and medical device companies. Dr. Li is actively engaged in identifying unmet needs in the healthcare space for which clinical and cost-effective technology can offer beneficial solutions. He is a graduate of Harvard, and completed his medical residency training at Massachusetts General Hospital in Boston. He serves as advisor and consultant to leading global public and private companies.

Mykol Larvie, Scientific Advisory Board Member
Recipient of three Harvard Medical Student Teaching awards in Principal Clinic Experience, Mykol Larvie is currently a radiologist in the Cleveland Clinic’s Divisions of Nuclear Medicine and Neuroradiology as well as the director of Functional and Molecular Neuroimaging. With a completed internship in the Department of Medicine as well residency in the Department of Radiology and fellowship in the Division of Neuroradiology at the Massachusetts General Hospital, Dr. Larvie specializes in PET examinations of the brain performed typically for the evaluation of neurodegenerative disease, seizure and tumor. He delivers didactic lectures and case conferences to residents and fellows six times per year and serves as a mentor and advisor to medical students, residents and fellows.

Nathan L. Guerette, Scientific Advisory Board Member
Nathan L. Guerette is the director and president of the Female Pelvic Medicine Institute of Virginia; an associate clinical professor in the division of Urogynecology and Pelvic Reconstructive Surgery at the Medical College of Virginia; a full clinical professor in Urogynecology and Pelvic Reconstructive Surgery at the Riverside Regional Medical Center; and the Robotic Surgery director at the Chippenham and Johnston Willis Medical Center. With a completed fellowship in urogynecology and pelvic reconstructive surgery at the Cleveland Clinic Foundation, Dr. Guerette has won seven awards in the medical and humanitarian departments. He has made nine media appearances, some of which were on PBS and NBC News. He has three board certifications and has ran a surgical mission trip to Trujillo, Peru, through Bon Secours.

Dr. Ashling O’Connor, Scientific Advisory Board Member
Currently a surgeon at the Comprehensive Breast Health Center of the Lahey Medical Center, Dr. O’Connor has won seven awards in the surgical department. She has completed a surgical internship at the Mater Misericordiae Hospital in Dublin as well as a breast surgery fellowship at the University of Massachusetts Interdisciplinary Breast Fellowship. She mentors medical students and surgical residents both in the operating room and in a clinical setting and enjoys biking and triathlons as well as trail and marathon running. She is certified in the Hidden Scar technique in breast surgery as well as in the advanced cardiac life support and is a member of the Protocol Review Committee Umass Memorial Medical Center, the New England Surgical Society and the American College of Surgeons.

Samir Awad, Scientific Advisory Board Member
Samir Awad has worked for the Department of Veterans Affairs since 2000. He has served as the operative care line associate executive, chief of general surgery, and medical director of the Surgical Intensive Care Unit at the MEDVAMC. Dr. Awad’s areas of specialty include liver, pancreas, and acute care surgery, as well as minimally invasive surgical procedures. He is a member of the Association for Academic Surgeons, the Society of University Surgeons, the American College of Surgeons, the Surgical Infection Society, and the Society for Critical Care Medicine. Dr. Awad has authored more than 100 peer-reviewed and invited publications and is the recipient of numerous awards for surgical and research achievements. Dr. Awad is certified by the American Board of Surgery and Surgical Critical Care.

Endonovo Therapeutics Inc. (ENDV), closed Wednesday's trading session at $0.002, off by 18.3673%, on 11,025,407 volume with 105 trades. The average volume for the last 3 months is 5,285,156 and the stock's 52-week low/high is $0.001599999/$0.040899999.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.